Bladder Cancer
Bladder cancer is a malignant neoplasm arising most commonly from the urothelial (transitional cell) lining of the urinary bladder, frequently presenting with painless hematuria.
Bladder Cancer
Bladder cancer refers to any malignant neoplasm arising from the tissues of the urinary bladder. The vast majority (~90%) originate from the urothelium (the transitional cell epithelium lining the bladder lumen), and are therefore termed urothelial carcinoma (UC) — previously known as transitional cell carcinoma (TCC) [1][2][3].
The name itself tells you the key concept:
- "Uro-" = urine/urinary system
- "-thelial" = epithelium
- "Carcinoma" = malignant tumour of epithelial origin
The single most important conceptual division in bladder cancer is whether the tumour has invaded the muscularis propria (detrusor muscle) or not, because this fundamentally changes prognosis and management [2][4].
High Yield: The critical question in bladder cancer is always: "Is it muscle-invasive or not?" This dictates whether you can manage conservatively (TURBT ± intravesical therapy) or need radical surgery.
2. Epidemiology
- Male predominance: M:F = 3:1 [1][2][3] — likely due to higher smoking rates and greater occupational chemical exposure in males historically, plus possible hormonal/receptor differences
- Median age of diagnosis ≈ 69 years (males), 71 years (females) [3]; most sources cite median ~70 years [1]
- Caucasians > other ethnicities [3]
- Second most prevalent malignancy after prostate cancer in middle-aged males [1]
Clinical Pearl
Presence of otherwise unexplained haematuria in anyone > 40 years old indicates urothelial cancer until proven otherwise. The most common cause of gross haematuria in a patient > 50 years old is bladder cancer [5].
- ~75% present with non-muscle invasive bladder cancer (NMIBC) — i.e., superficial disease (Ta, Tis, T1)
- ~25% present with muscle-invasive bladder cancer (MIBC) — i.e., ≥T2
- Of NMIBC, recurrence rate is notoriously high (~50–70% recur, ~10–30% progress to MIBC)
3. Anatomy and Function
Understanding bladder cancer requires knowing the layers of the bladder wall, because staging is defined by depth of invasion through these layers.
| Layer | Description | Staging Relevance |
|---|---|---|
| Urothelium (transitional epithelium) | 3–7 cell layers thick; waterproof barrier; stretches as bladder fills | Tis (CIS) and Ta (papillary, non-invasive) |
| Lamina propria (subepithelial connective tissue) | Loose connective tissue with blood vessels and nerves; contains the muscularis mucosae (a thin, often discontinuous smooth muscle layer — do NOT confuse with muscularis propria!) | T1 (invades lamina propria but NOT muscularis propria) |
| Muscularis propria (detrusor muscle) | Thick smooth muscle in 3 layers (inner longitudinal → middle circular → outer longitudinal); responsible for bladder contraction during micturition | T2a (inner half) and T2b (outer half) — this is the critical boundary |
| Perivesical fat (adventitia/serosa) | Adipose tissue surrounding the bladder; only the superior surface has a peritoneal covering (serosa) | T3 (extends through muscle into perivesical tissue) |
| Adjacent organs | Prostate, seminal vesicles, uterus, vagina, pelvic sidewall, abdominal wall | T4 (invades adjacent structures) |
Common Exam Mistake
Do NOT confuse the muscularis mucosae (a thin, discontinuous muscle layer within the lamina propria) with the muscularis propria (detrusor). T1 tumours invade the lamina propria and may reach the muscularis mucosae, but are still "non-muscle invasive." The term "muscle-invasive" specifically means invasion of the muscularis propria (detrusor).
- The trigone (triangle between the two ureteric orifices and the internal urethral meatus) is a common site for tumours; tumours here can obstruct the ureters, causing hydronephrosis
- The dome/fundus is derived from the urachus (embryological remnant connecting the bladder apex to the umbilicus via the median umbilical ligament) — adenocarcinoma can arise from urachal remnants here [1][3]
- The bladder receives blood supply from the superior and inferior vesical arteries (branches of the internal iliac artery)
- Lymphatic drainage is to the obturator, internal iliac, external iliac, and presacral lymph nodes — this is the basis for lymph node dissection at radical cystectomy
- Venous drainage is via the vesical venous plexus → internal iliac veins → explains potential for haematogenous spread
The entire urothelium from the renal pelvis to the urethra is exposed to the same carcinogens (in the urine). This means:
- Multifocal tumours are characteristic — a single exposure can produce synchronous or metachronous tumours anywhere along the urinary tract
- Patients with upper tract urothelial carcinoma (renal pelvis/ureter) have a 17% chance of concurrent bladder cancer (due to "drop metastasis" — cancer cells shed and seed distally along urine flow) [1]
- Conversely, patients with bladder cancer have only ~2% chance of upper tract disease — because urine flows antegradely (downward), seeding is less likely in the retrograde direction [1]
- This is why surveillance of the entire urothelium is necessary after any urothelial cancer diagnosis
4. Risk Factors and Aetiology
Bladder cancer risk factors are predominantly environmental — family history confers only a mild increase in risk, and even that is much more prominent among smokers and early-onset cases [3].
4.1 Risk Factors for Urothelial Carcinoma (90% of cases)
- Most important risk factor for bladder cancer
- Confers a 2–5× increased risk; accounts for ~50% of all bladder cancers [3]
- Mechanism: Polycyclic aromatic hydrocarbons (PAHs) and aromatic amines (e.g., 2-naphthylamine, 4-aminobiphenyl) in tobacco smoke are absorbed systemically → metabolized in the liver → excreted by the kidneys into urine → prolonged contact with the urothelium → DNA damage → mutations (particularly TP53, RB1, FGFR3) → malignant transformation
- Duration and intensity of smoking both correlate with risk; risk decreases after cessation but never returns to baseline
- Accounts for ~10–20% of bladder cancers
- Latency period can be > 20 years (this is a classic exam point — a patient retired 25 years ago from a rubber factory can still present with bladder cancer now) [3]
- Exposure to aromatic amines and chemicals used in dye, rubber, leather, textile, and paint industries [4]
- Specific chemicals: aniline dyes, benzidine, 2-naphthylamine, 4-aminobiphenyl, PAHs, benzene, diesel exhaust
- At-risk occupations: textile workers, dye workers, tyre rubber and cable workers, petrol workers, leather workers, shoe manufacturers and cleaners, painters, hairdressers, lorry drivers, metal workers, drill press operators, chemical workers, miners, cement workers, transport operators, excavating-machine operators, rodent exterminators, sewage workers [1][3]
- Cyclophosphamide: 9× increased risk with latency < 10 years [3]; its metabolite acrolein is directly toxic to the urothelium → also causes haemorrhagic cystitis [1]
- (This is why MESNA — "mercaptoethane sulfonate sodium" — is co-administered with cyclophosphamide; it binds acrolein in urine to neutralize it)
- Aristolochic acid in TCM: a well-recognized carcinogen in Hong Kong — should always be screened in the history [3][5]; causes a characteristic mutational signature (A:T → T:A transversions) and also causes Balkan endemic nephropathy / Chinese herb nephropathy
- Chronic analgesic abuse (particularly phenacetin-containing analgesics) [3]
- Pelvic radiation therapy (for rectal, cervical, prostate, testicular cancers) [1][3] — 2–4× risk, latency 5–10 years
- Upper tract urothelial carcinoma: field cancerization concept — the same carcinogen exposure affects the entire urothelium; also "drop metastasis" (cells seed distally) [1]
- Chronic cystitis: chronic inflammation → metaplasia → dysplasia → malignancy (more strongly linked to SCC than UCC)
- Chronic urinary catheter placement > 10 years: chronic irritation → squamous metaplasia → SCC [3]
- HPV infection [3] — emerging evidence, not as strongly established as in cervical cancer
- Bladder augmentation: ~1% risk of CA bladder [3]
- Only a mild increase in risk; much more prominent among smokers and early-onset cases [3]
- Rare hereditary syndromes: Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) is associated with upper tract urothelial carcinoma
SCC arises from squamous metaplasia of the urothelium due to chronic irritation/inflammation. The key risk factors are:
- Schistosomiasis (Schistosoma haematobium) — endemic in Egypt and other parts of Africa/Middle East [2][4]
- Mechanism: ova deposited in the bladder wall → granulomatous inflammation → chronic cystitis → squamous metaplasia → dysplasia → SCC
- Common in chronic irritation or schistosomiasis; often presents late with poor prognosis [4]
- Always ask TOCC (travel, occupation, contact, cluster) — particularly travel to Egypt [2]
- Bladder stones: chronic mechanical irritation → squamous metaplasia → SCC [1][2]
- Long-term indwelling catheter use [1][2][4]: patients with spinal cord injuries who have long-term indwelling catheters have a 16–20× risk of developing SCC (NOT UCC — because this is chronic irritation-mediated, not carcinogen-mediated) [1]
- Chronic bladder irritation and infections [4]
- Urachal remnants: the urachus is the embryological connection between the bladder dome and the allantois (umbilicus). Remnant tissue at the bladder dome can undergo malignant transformation → adenocarcinoma arising from the bladder fundus [1][3]
- Bladder exstrophy: a rare congenital malformation where the bladder is exposed → chronic irritation → metaplasia → adenocarcinoma [1]
- Intestinal metaplasia (e.g., from chronic irritation or following bladder augmentation with bowel segments)
- Should always be distinguished from secondary (metastatic) adenocarcinoma from colon, rectum, prostate, or uterine cervix — which are actually the vast majority of adenocarcinomas seen in the bladder [3]
- Small cell carcinoma: Rare but very aggressive [4] — analogous to small cell lung cancer; neuroendocrine origin; often presents with metastatic disease; managed with platinum-based chemotherapy
- Sarcomatoid carcinoma: aggressive, poor prognosis [4] — biphasic tumour with both epithelial and mesenchymal elements
5. Pathophysiology
Bladder cancer develops along two distinct molecular pathways, which correlate with the clinical behaviour:
| Feature | Low-Grade Papillary Pathway | High-Grade / CIS Pathway |
|---|---|---|
| Initiating mutation | FGFR3 activating mutations (~70%) | TP53 and RB1 loss-of-function mutations |
| Morphology | Papillary (Ta), well-differentiated | Flat (CIS, Tis) or sessile/solid, poorly differentiated |
| Grade | Low-grade (G1/G2 old WHO) | High-grade (G3 old WHO) |
| Behaviour | High recurrence (~50–70%) but low progression (~5–15%) | Lower recurrence but high progression to muscle-invasion (~50–75%) |
| Clinical stage | Typically remains NMIBC (Ta) | Tends to progress to MIBC (≥T2) |
| Prognosis | Generally good | Poor if untreated |
Why does this matter clinically?
- A small, low-grade Ta papillary tumour may recur multiple times but rarely kills the patient — it's a "nuisance" tumour requiring lifelong surveillance
- A CIS (Tis) or high-grade T1 tumour, despite being technically "superficial" (non-muscle invasive), has a high risk of progression to muscle-invasive disease and must be treated aggressively (intravesical BCG or even early radical cystectomy)
Tumour neovascularization creates fragile, abnormal blood vessels on the tumour surface. These bleed into the bladder lumen → blood mixes with urine → painless gross haematuria. There is no stretching of the renal capsule (which causes pain in kidney cancer) and no ureteric obstruction (which causes colic in stones), hence the haematuria is classically painless — unless the tumour is advanced enough to invade nerves or obstruct the ureter.
The entire urothelium is bathed in carcinogen-containing urine. Genetic damage occurs across wide fields of urothelium simultaneously ("field effect" or "field cancerization"). This explains:
- Multifocal tumours (multiple tumours in the bladder at the same time)
- Pan-urothelial risk (tumours at renal pelvis, ureter, and bladder)
- High recurrence rate (even after complete resection, new tumours arise from other areas of damaged urothelium)
- Intraluminal seeding (tumour cells shed into urine and implant at distant urothelial sites) [1]
- Direct extension: into perivesical fat → adjacent organs (prostate, uterus, vagina, pelvic sidewall)
- Lymphatic spread: to obturator → internal iliac → external iliac → common iliac → para-aortic nodes
- Haematogenous spread: via vesical venous plexus → systemic circulation
- Common sites of metastasis: Liver, Lung, Bone [1] (also brain, less commonly)
6. Classification
| Type | Prevalence | Key Features |
|---|---|---|
| Urothelial Carcinoma (Transitional Cell Carcinoma) | ~90% | The most common type [4] |
| Squamous Cell Carcinoma | ~5–9% | Common in chronic irritation or schistosomiasis; often presents late with poor prognosis [4] |
| Adenocarcinoma | Rare (~1–2%) | From urachal remnants or metaplasia; must distinguish from secondary tumours [4] |
| Small cell carcinoma | Rare | But very aggressive [4]; neuroendocrine differentiation |
| Sarcomatoid carcinoma | Very rare | Aggressive, poor prognosis [4]; biphasic morphology |
| Non-epithelial | Very rare | Sarcoma, carcinosarcoma, paraganglioma, melanoma, lymphoma [3] |
| Secondary (metastatic) | Variable | From colon, rectum, prostate, uterine cervix [3] |
| 2004/2016 WHO Classification | 1973 WHO Classification | Clinical Significance |
|---|---|---|
| PUNLMP (Papillary Urothelial Neoplasm of Low Malignant Potential) | — | Minimal atypia; very low risk of progression; benign behaviour but needs surveillance |
| Low-grade urothelial carcinoma | Grade 1 / Grade 2 | Recurs frequently but rarely progresses to invasion |
| High-grade urothelial carcinoma | Grade 2 / Grade 3 | High risk of recurrence AND progression to muscle-invasive disease |
T — Primary Tumour
| Stage | Description | Category |
|---|---|---|
| Tis | Carcinoma in situ ("flat" high-grade tumour confined to urothelium) | NMIBC |
| Ta | Non-invasive papillary carcinoma (confined to urothelium, does NOT invade lamina propria) | NMIBC |
| T1 | Invades subepithelial connective tissue (lamina propria) but NOT muscularis propria | NMIBC |
| T2a | Invades superficial muscularis propria (inner half of detrusor) | MIBC |
| T2b | Invades deep muscularis propria (outer half of detrusor) | MIBC |
| T3a | Microscopically extends beyond muscularis propria into perivesical fat | MIBC |
| T3b | Macroscopically extends beyond muscularis propria (extravesical mass) | MIBC |
| T4a | Invades prostate stroma, seminal vesicles, uterus, or vagina | MIBC |
| T4b | Invades pelvic sidewall or abdominal wall | MIBC |
N — Regional Lymph Nodes
| Stage | Description |
|---|---|
| N0 | No regional LN metastasis |
| N1 | Single LN in true pelvis (obturator, internal/external iliac, presacral) |
| N2 | Multiple LNs in true pelvis |
| N3 | Common iliac LN metastasis |
M — Distant Metastasis
| Stage | Description |
|---|---|
| M0 | No distant metastasis |
| M1a | Non-regional lymph nodes (beyond common iliac) |
| M1b | Other distant metastasis (liver, lung, bone) |
The Most Important Staging Concept
Non-muscle invasive bladder cancer (NMIBC) = Tis, Ta, T1 → treated with TURBT ± intravesical therapy; surveillance
Muscle invasive bladder cancer (MIBC) = T2 or above → requires radical cystectomy ± neoadjuvant chemotherapy or chemoradiation [1][2][3][4]
Muscle-invasive tumours (T2 or above) are mostly high-grade tumours [1].
NMIBC is further stratified to guide adjuvant treatment decisions:
| Risk Group | Features | Recurrence/Progression Risk |
|---|---|---|
| Low risk | Single, small (< 3 cm), Ta, low-grade, no CIS | Low recurrence, very low progression |
| Intermediate risk | Multiple OR recurrent OR large (≥ 3 cm) Ta low-grade, no CIS | Moderate recurrence, low progression |
| High risk | Any T1, any high-grade, any CIS, multiple/recurrent/large Ta high-grade | High recurrence, high progression to MIBC |
7. Clinical Features
7.1 Symptoms
- The cardinal symptom of bladder cancer
- Typically intermittent and present throughout micturition (bladder in origin) [3]
- Why throughout? Because the tumour is in the bladder — blood mixes with all the urine stored there, so the entire stream is blood-stained (cf. initial stream = urethral, terminal stream = bladder neck/prostatic urethra) [5]
- Painless because the tumour grows into the bladder lumen without stretching the capsule or obstructing flow (in early disease). Pain implies invasion of nerves, perivesical tissues, or ureteric obstruction → advanced disease
- Risk of bladder CA is ~10–20% in gross haematuria and 2–5% in microscopic haematuria [3]
- The haematuria is intermittent — patients may have one episode, then nothing for weeks/months, leading to false reassurance. A single episode of painless gross haematuria in anyone > 40 must be investigated for malignancy [1][5]
- Clot passage may occur → can cause clot retention (acute urinary retention due to blood clots obstructing the urethra)
High Yield: Most common cause of gross haematuria in a patient > 50 years old is bladder cancer [5].
- Irritative symptoms (~1/3 of patients): frequency, urgency ± urge incontinence, nocturia [2][3]
- Why? The tumour (especially CIS, which is flat and diffuse) irritates the bladder mucosa → stimulates stretch/pain receptors in the detrusor → premature signals of bladder fullness → urgency and frequency
- CIS (carcinoma in situ) classically presents with irritative LUTS rather than haematuria — this is a crucial point because CIS is a flat, high-grade lesion that is invisible on standard white-light cystoscopy and may mimic UTI or overactive bladder [3]
- Nocturia occurs because the irritated bladder cannot tolerate even the normal volumes produced overnight
- Obstructive symptoms (less common): hesitancy, weak stream ± straining, intermittence, terminal dribbling, incomplete voiding [2][3]
- Why? Tumour at the bladder neck or obstructing a ureteric orifice can physically impede urine flow; large intravesical tumours reduce functional bladder capacity and interfere with detrusor contraction
- Strangury (painful, frequent passage of small amounts of urine with a sense of incomplete emptying) can occur with advanced tumours near the bladder neck [3]
Clinical Pearl
New-onset irritative LUTS in an older patient that does NOT respond to empirical antibiotic treatment should raise alarm for CIS or bladder cancer. Don't just prescribe antibiotics for "recurrent UTIs" — investigate!
- Usually indicates at least muscle-invasive disease — pain is NOT a feature of early bladder cancer
- Flank pain: due to tumour at the ureteric orifice level causing ureteric obstruction → hydronephrosis → capsular stretching of the kidney → loin/flank pain. Usually indicates muscle-invasive disease [3]
- Suprapubic pain: due to locally advanced tumour directly invading perivesical soft tissues and nerves, or obstructing the bladder outlet [3]
- Pain at other sites: due to metastatic disease (bone pain, abdominal pain from liver metastases, headache from brain metastases)
- Loss of appetite, unintentional weight loss, fatigue, night sweats
- Indicates advanced or metastatic disease (poor prognosis) [3]
- Why? Tumour cytokine production (TNF-α, IL-6) → systemic inflammatory response → cancer cachexia
- Pneumaturia (air in urine): pathognomonic of vesicocolic fistula — tumour erodes through the bladder wall into the adjacent colon/sigmoid [3]
- Vaginal leakage of urine (continuous incontinence): suggests vesicovaginal fistula — tumour erodes into the vagina [3]
- Faecaluria (faecal matter in urine): also from vesicoenteric fistula
- Recurrent UTIs: tumour surface → bacterial colonization; fistula → enteric organisms in urine
7.2 Signs
Physical examination in bladder cancer is often normal in early disease. Signs become apparent with advanced or metastatic disease.
- Cachexia: muscle wasting, temporal wasting — indicates advanced/metastatic disease (cytokine-mediated catabolism)
- Pallor: from chronic haematuria → iron deficiency anaemia, or anaemia of chronic disease
- Lymphadenopathy: palpable inguinal or supraclavicular (Virchow's node/left supraclavicular) lymph nodes — indicates lymphatic metastasis
- Palpable bladder: large tumour mass or clot retention causing urinary retention → distended bladder palpable suprapubically
- Palpable flank/loin mass: hydronephrotic kidney from ureteric obstruction by the tumour
- Hepatomegaly: from hepatic metastases; may be tender, nodular, hard
- Ascites: peritoneal carcinomatosis (rare)
- Bimanual examination under anaesthesia is performed at the time of TURBT to assess:
- Bladder mass: palpable through the rectum (in males) or vagina (in females)
- Mobility: a mobile mass suggests organ-confined disease; a fixed mass (adherent to the pelvic sidewall) suggests T4b disease (pelvic sidewall invasion) — this is unresectable
- This is a clinical staging technique that helps determine operability
- Unilateral or bilateral lower limb oedema: from pelvic lymph node metastases compressing the iliac veins → venous obstruction → oedema
- Deep vein thrombosis (DVT): malignancy is a hypercoagulable state (Trousseau syndrome — cancer cells produce tissue factor and other procoagulants → activation of coagulation cascade)
| Clinical Feature | Pathophysiological Explanation |
|---|---|
| Painless gross haematuria | Tumour neovascularization → fragile vessels bleed into lumen; no nerve/capsule involvement in early disease |
| Throughout-stream haematuria | Blood mixes with entire bladder content (bladder origin) |
| Irritative LUTS (frequency, urgency) | Tumour (esp CIS) irritates bladder mucosa → premature detrusor signals |
| Obstructive LUTS | Tumour at bladder neck or ureteric orifice impedes flow |
| Flank pain | Ureteric obstruction → hydronephrosis → renal capsule stretch |
| Suprapubic pain | Direct perivesical invasion / bladder outlet obstruction |
| Bone pain | Haematogenous metastasis to bone |
| Constitutional symptoms | Tumour cytokines (TNF-α, IL-6) → systemic inflammation → cachexia |
| Pneumaturia | Vesicocolic fistula (tumour erodes into colon) |
| Continuous urinary incontinence (vaginal) | Vesicovaginal fistula |
| Pallor | Chronic blood loss → iron deficiency anaemia |
| Lower limb oedema | Pelvic LN metastases → iliac vein compression |
| Fixed pelvic mass on EUA | T4b invasion of pelvic sidewall |
High Yield Summary
Definition: Malignant neoplasm of the bladder, ~90% urothelial carcinoma. Key question: muscle-invasive or not?
Epidemiology: 9th commonest cancer worldwide; M:F = 3:1; median age ~70; 9th commonest male cancer in HK.
Risk Factors (UCC): Smoking (#1, 2–5× risk, ~50% attributable), occupational chemical exposure (aromatic amines; latency > 20 years), cyclophosphamide, aristolochic acid (TCM — HK!), pelvic radiation, upper tract UC (field cancerization).
Risk Factors (SCC): Schistosomiasis, bladder stones, long-term indwelling catheter (16–20× risk for SCC).
Risk Factors (Adeno): Urachal remnants, bladder exstrophy.
Pathology: Urothelial (90%), SCC (5–9%), Adenocarcinoma (~1%), Small cell (rare but very aggressive), Sarcomatoid (rare, poor prognosis).
Two-pathway model: Low-grade papillary (FGFR3 mutations, high recurrence, low progression) vs High-grade/CIS (TP53/RB1 loss, high progression to MIBC).
Staging: NMIBC (Tis, Ta, T1) vs MIBC (≥T2). Muscle-invasive tumours are mostly high-grade.
Cardinal symptom: Painless gross haematuria throughout the stream. Any unexplained haematuria > 40 years = cancer until proven otherwise.
CIS pitfall: Presents with irritative LUTS, NOT visible haematuria — mimics UTI/OAB.
Advanced disease signs: Pain (flank, suprapubic, bony), constitutional symptoms, pneumaturia (vesicocolic fistula), fixed pelvic mass on EUA (T4b).
Metastases: Liver, lung, bone.
Field cancerization: Multifocal occurrence; upper tract → 17% concurrent bladder CA; bladder → only 2% upper tract CA (antegrade flow).
Active Recall - Bladder Cancer (Definition to Clinical Features)
[1] Senior notes: felixlai.md (Urothelial bladder cancer section) [2] Senior notes: maxim.md (Bladder cancer section) [3] Senior notes: Ryan Ho Urogenital.pdf (Section 7.4 / 7.4.1 Bladder Cancer, pp. 152–153) [4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 8, 21) [5] Senior notes: Ryan Ho Fundamentals.pdf (Haematuria approach, pp. 342, 345)
Differential Diagnosis of Bladder Cancer
The differential diagnosis (DDx) of bladder cancer is really the differential diagnosis of its cardinal presenting symptom — haematuria — plus the DDx of its secondary presentations (LUTS, pelvic pain). The clinical approach is: a patient walks in with haematuria → you must systematically consider all possible causes, determine the most likely diagnosis, and then investigate accordingly.
The guiding principle is straightforward: painless gross haematuria in > 35 years old = malignancy until proven otherwise [3][5]. But you still need to think broadly before narrowing down.
The most logical way to build a DDx for haematuria is to walk along the urinary tract from the kidney down to the urethra, asking: "What at each level could bleed?"
Additionally, you must distinguish between:
- Glomerular haematuria (medical/nephrological) — dysmorphic RBCs, RBC casts, proteinuria, smoky brown "Coca-Cola" urine without clots
- Non-glomerular / urological haematuria — isomorphic (normal-shaped) RBCs, may have clots (urokinase in glomerular filtrate normally prevents clot formation, so clots suggest a post-glomerular source), bright red blood [2][5][6]
Why No Clots in Glomerular Bleeding?
Urokinase is present in the glomerular filtrate and dissolves fibrin. So blood that passes through the glomerulus cannot form clots. If a patient passes blood clots, the bleeding source is urological (post-glomerular) — stone, tumour, infection, trauma. This is a simple but powerful bedside discriminator.
| Anatomical Location | Category | Differential Diagnosis | Key Distinguishing Features |
|---|---|---|---|
| Kidney — Glomerular | Glomerulonephritis (GN) | IgA nephropathy, post-infectious GN, Alport syndrome, thin basement membrane disease, lupus nephritis, ANCA vasculitis (GPA, MPA), Goodpasture syndrome | Smoky brown urine without clots, dysmorphic RBCs / RBC casts on microscopy, concomitant proteinuria, features of nephritic syndrome (HTN, oedema, oliguria), systemic signs (rash, purpura, haemoptysis) [5][6] |
| Kidney — Tubular / Parenchymal | Polycystic kidney disease | Bilateral flank masses, insidious HTN, family history (autosomal dominant) [5][6] | |
| Pyelonephritis | High fever, rigors, vomiting, loin pain and tenderness [5][6] | ||
| Renal infarction | Acute loin pain, risk factors for embolism (AF, endocarditis), raised LDH [5][6] | ||
| Renal vein thrombosis | Loin pain, nephrotic syndrome, risk factors (nephrotic syndrome, malignancy) | ||
| Renal cell carcinoma (RCC) | Classic triad (rare): flank pain, painless haematuria, palpable flank mass; constitutional symptoms; paraneoplastic phenomena (HTN, hypercalcaemia, polycythaemia); left varicocele (left renal vein obstruction) [5][6] | ||
| Renal pelvis urothelial carcinoma | Haematuria, obstructive flank pain (20–40%), field cancerization with bladder CA [3] | ||
| AV malformation | Intermittent painless haematuria, young patient, may have bruit | ||
| Ureter | Ureteric stone | Unilateral flank colic radiating to groin (classic renal colic), nausea/vomiting, restlessness [5][6] | |
| Upper tract urothelial carcinoma | Haematuria + obstructive flank pain; field cancerization concept [1][3] | ||
| Bladder | CA bladder | Painless gross haematuria throughout stream; irritative LUTS (esp CIS); constitutional symptoms if advanced [1][2][3] | |
| Bladder stones | Irritative LUTS + suprapubic pain worsened by movement; interruption of urinary stream (stone intermittently blocks bladder neck) [5][6] | ||
| UTI / Cystitis | Dysuria, frequency, urgency, suprapubic discomfort, foul-smelling/cloudy urine, fever; positive MSU culture [5][6] | ||
| Non-infectious cystitis | Radiation cystitis, cyclophosphamide cystitis, ketamine cystitis | History of pelvic RT, cyclophosphamide/ifosfamide use, or ketamine abuse [5][6][7] | |
| Interstitial cystitis | Chronic pelvic pain, frequency, urgency; diagnosis of exclusion; more common in females | ||
| Prostate | BPH | Advanced age male, predominantly obstructive LUTS (hesitancy, weak stream, straining, dribbling, incomplete emptying); diagnosis by exclusion (presence of BPH should NOT dissuade from further haematuria workup) [5][6][7] | |
| CA prostate | Obstructive LUTS, hard irregular prostate on DRE, elevated PSA, bone pain if metastatic [5][6] | ||
| Prostatitis | Perineal pain, dysuria, fever, tender prostate on DRE | ||
| Urethra | Urethral stricture | History of urological instrumentation, STI (gonococcal urethritis), poor stream | |
| Urethral trauma | History of catheterisation, straddle injury, pelvic fracture | ||
| Systemic / Other | Bleeding diathesis | Anticoagulant/antiplatelet therapy, coagulopathy, thrombocytopenia | Seldom causes haematuria on its own — 81% have an underlying urinary cause [5][6]; bruising, bleeding gums, epistaxis |
| Exercise-induced haematuria | Transient, after strenuous exercise, resolves with rest; diagnosis of exclusion [5][6] | ||
| Benign idiopathic haematuria | May be associated with exercise, febrile illness, vaccination; may be familial; diagnosis of exclusion [5][6] | ||
| Menstrual contamination | Must rule out by repeating urinalysis after menses; cyclic haematuria during menses → consider urinary tract endometriosis [7] | ||
| Pigmenturia (not true haematuria) | Haemoglobinuria, myoglobinuria, beetroot, rifampicin | Dipstick positive for "blood" but no RBCs on microscopy (dipstick detects haem, not RBCs specifically) |
High Yield: The causes of haematuria by frequency in a urological workup: UTI (13%), CA bladder (12%), medical renal disease (10%), stone disease (4%), RCC (0.6%), CA prostate (0.4%) [3]. Bladder cancer is the second most common cause of haematuria in a urological setting and the most common cause of gross haematuria in patients > 50 years old [5].
Bladder cancer can present with irritative LUTS (especially CIS) or obstructive LUTS (if the tumour obstructs the bladder neck or ureteric orifice). You must differentiate from other causes:
| LUTS Pattern | DDx | Key Distinguishing Feature |
|---|---|---|
| Irritative (storage) — frequency, urgency, nocturia | CA bladder (esp CIS), UTI/cystitis, bladder stones, ketamine cystitis, interstitial cystitis, overactive bladder (neurogenic or idiopathic), radiation cystitis | CIS: elderly + risk factors + refractory to antibiotics; UTI: dysuria + positive culture; Bladder stone: pain with movement; OAB: diagnosis of exclusion [7] |
| Obstructive (voiding) — hesitancy, weak stream, straining, dribbling | BPH, CA prostate, urethral stricture, bladder neck contracture, CA bladder (large tumour at bladder neck) | BPH: symmetrically enlarged smooth prostate on DRE; CA prostate: hard irregular prostate + elevated PSA; Stricture: history of instrumentation/STI [7] |
Important Exam Point
New-onset irritative LUTS in an elderly patient that does NOT respond to antibiotics → must consider CIS of the bladder. Do NOT keep prescribing antibiotics for "recurrent UTIs" without a cystoscopy in an at-risk patient (male, > 40, smoker). CIS is flat, high-grade, and easily missed on standard imaging — it requires cystoscopy (± fluorescence/NBI) for detection [1][3].
If a mass is identified in the bladder (e.g., on CT urogram or cystoscopy), the DDx includes:
| Category | Diagnosis | Distinguishing Features |
|---|---|---|
| Primary malignant | Urothelial carcinoma (90%) | Most common; papillary or sessile; field cancerization |
| Squamous cell carcinoma | History of chronic irritation / schistosomiasis; keratinising on biopsy | |
| Adenocarcinoma | Urachal remnant (dome location); must exclude secondary (colorectal, prostate) | |
| Small cell carcinoma | Rare but very aggressive [4]; neuroendocrine markers on IHC | |
| Sarcomatoid carcinoma | Aggressive, poor prognosis [4]; biphasic on histology | |
| Non-epithelial (sarcoma, lymphoma, melanoma, paraganglioma) | Very rare; specific histological/IHC features [3] | |
| Secondary malignant | Direct invasion from colon, rectum, prostate, uterine cervix [3] | History of known primary malignancy; imaging shows contiguous invasion |
| Metastatic (melanoma, stomach, breast) | Very rare; history of distant primary | |
| Benign | Urothelial papilloma / inverted papilloma | Small, typically solitary, regular papillary architecture; benign histology |
| Nephrogenic adenoma | History of prior bladder surgery/trauma/infection; benign but mimics carcinoma | |
| Cystitis cystica / cystitis glandularis | Chronic inflammatory change; benign but can mimic tumour | |
| Endometriosis | Female, cyclic symptoms, submucosal bluish nodule on cystoscopy | |
| Blood clot | History of recent haematuria; mobile, no vascular pattern; resolves | |
| Foreign body | History of self-insertion or iatrogenic (retained catheter fragment, surgical material) |
| Feature | Points Toward Bladder Cancer | Points Away from Bladder Cancer |
|---|---|---|
| Age | > 40 years, elderly | Young (< 40 → think GN, stone, UTI) |
| Sex | Male (M:F = 3:1) | — |
| Haematuria character | Painless, gross, throughout stream, intermittent | Painful → stone, UTI; initial → urethra; terminal → prostate/bladder neck; smoky brown without clots → GN |
| Blood clots | Present (urological source) | Absent with dysmorphic RBCs → GN |
| LUTS | Irritative (esp. refractory to Abx → CIS) | Obstructive only → BPH/CA prostate |
| Smoking / occupational exposure | Strong risk factor | — |
| Cyclophosphamide / aristolochic acid | Strong risk factor | — |
| Recent URTI | Less likely bladder CA | IgA nephropathy (synpharyngitic haematuria) |
| Systemic features | Constitutional Sx → advanced CA | Rash/arthralgia → SLE/vasculitis; haemoptysis → pulmonary-renal syndrome |
| Response to antibiotics | No response (CIS mimics UTI) | Resolves → likely UTI |
Any of the following in a patient with haematuria should prompt urgent cystoscopy and upper tract imaging:
- Age > 40 with any unexplained haematuria (gross or microscopic)
- Painless gross haematuria at any age
- Visible haematuria with risk factors for malignancy (smoking, occupational exposure, cyclophosphamide, aristolochic acid, pelvic RT, chronic catheter) [5]
- Persistent microscopic haematuria (≥ 3 RBC/HPF on ≥ 2 out of 3 properly collected samples) after exclusion of benign causes
- Recurrent UTIs in a male or post-menopausal female (must exclude underlying malignancy)
- New-onset irritative LUTS refractory to treatment in an at-risk patient
Common Exam Mistake
Presence of BPH should NOT dissuade from further evaluation of haematuria — older men with BPH are also at risk for bladder cancer, RCC, and other urological malignancies. Always investigate haematuria fully even if BPH is present [7].
High Yield Summary
The DDx of bladder cancer is essentially the DDx of haematuria, organized anatomically from kidney to urethra plus systemic causes.
Most common cause of haematuria overall: UTI (13%). Most worrying: malignancy (CA bladder 12%, RCC 0.6%) [2][3].
Most common cause of gross haematuria in patients > 50: bladder cancer [5].
Key discriminators:
- Glomerular vs urological: dysmorphic RBCs/casts/proteinuria = glomerular; isomorphic RBCs ± clots = urological
- Painless = malignancy until proven otherwise; painful = stone, UTI, infarction
- Throughout stream = bladder/upper tract; initial = urethra; terminal = bladder neck/prostate
- Blood clots = urological (urokinase in glomerular filtrate prevents clots in GN)
- Irritative LUTS refractory to antibiotics in elderly = CIS until proven otherwise
DDx of bladder mass: Primary malignant (urothelial 90%, SCC, adeno, small cell, sarcomatoid), secondary malignant (colon, rectum, prostate, cervix), benign (papilloma, nephrogenic adenoma, cystitis cystica, endometriosis, blood clot)
BPH does NOT exclude malignancy — always investigate haematuria fully even if BPH is present.
Active Recall - Bladder Cancer DDx
References
[1] Senior notes: felixlai.md (Urothelial bladder cancer section) [2] Senior notes: maxim.md (Bladder cancer section; Haematuria section) [3] Senior notes: Ryan Ho Urogenital.pdf (Section 7.4 / 7.4.1 Bladder Cancer, pp. 152–155; Section 7.1 Approach to Haematuria, pp. 130–132) [4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 8, 21) [5] Senior notes: Ryan Ho Fundamentals.pdf (Haematuria approach, pp. 340–345) [6] Senior notes: Ryan Ho Urogenital.pdf (Section 7.1 Approach to Haematuria, p. 130) [7] Senior notes: felixlai.md (Differential diagnosis of haematuria section; Differential diagnosis of LUTS section)
Diagnostic Criteria, Algorithm, and Investigations for Bladder Cancer
Unlike some conditions that have formal diagnostic criteria (e.g., Duke criteria for endocarditis, Jones criteria for rheumatic fever), bladder cancer is diagnosed by histopathological examination of tissue obtained at cystoscopy + biopsy/TURBT. There is no blood test, imaging feature, or clinical criterion that alone confirms the diagnosis.
The diagnostic process is therefore a stepwise algorithm:
- Suspicion → raised by symptoms (haematuria, LUTS) and risk factors
- Initial workup → blood tests, urinalysis, urine cytology
- Visualisation → cystoscopy (gold standard for lower tract) + upper tract imaging (CTU)
- Histopathological confirmation → biopsy or TURBT (provides both diagnosis AND staging)
- Staging workup → to determine NMIBC vs MIBC vs metastatic → guides management
High Yield: Despite advancing imaging and urine biomarkers, non-invasive tests alone CAN NEVER replace cystoscopy/TURBT for diagnosis of CA bladder [3].
Investigation Modalities — Detailed Breakdown
| Test | Purpose | Key Findings / Interpretation |
|---|---|---|
| CBC with differentials | Assess for anaemia (chronic blood loss), leukocytosis (infection) | Microcytic hypochromic anaemia → chronic haematuria-related iron deficiency; normocytic → anaemia of chronic disease; leukocytosis → concurrent UTI or advanced disease [1][5] |
| RFT (urea, creatinine, eGFR, electrolytes) | Assess baseline renal function; detect obstruction | Elevated creatinine/urea → bilateral ureteric obstruction by tumour or solitary functioning kidney obstructed; essential before contrast imaging [1][5] |
| LFT | Metastatic workup (liver metastases) | Elevated ALP, GGT, transaminases → hepatic metastases; elevated ALP alone → also consider bony metastases [1] |
| Clotting profile | Rule out coagulopathy as contributor to haematuria | Prolonged PT/APTT → bleeding diathesis (but 81% of such patients still have an underlying urological cause) [5] |
Why check these first? Because they establish whether the patient is safe for contrast imaging (RFT), guide anaesthetic fitness assessment for TURBT (CBC, clotting), and begin the metastatic workup (LFT).
B. Urinalysis and Urine Tests
| Component | What to Look For | Interpretation |
|---|---|---|
| Dipstick | Blood, leukocytes, nitrites, protein | Confirms haematuria; leukocytes + nitrites suggest UTI; protein suggests glomerular disease |
| Microscopy | RBC morphology, WBCs, casts, crystals | Isomorphic RBCs ± clots → urological (non-glomerular) source; Dysmorphic RBCs (especially acanthocytes) + RBC casts → glomerular disease; WBC > 5/HPF (pyuria) → infection [1][7] |
Why does RBC morphology matter? Dysmorphic RBCs are distorted by passing through damaged glomerular basement membrane and osmotic stress in the tubules. Isomorphic RBCs have not undergone this process — they entered the urine from a post-glomerular source (stone, tumour, infection). This single microscopy finding separates "nephrology" from "urology" haematuria.
- Rule out UTI as the cause of haematuria
- Important because UTI is the most common overall cause of haematuria (13%) [3]
- If culture positive, treat the UTI → then repeat urinalysis; if haematuria persists, still investigate for malignancy
This is a key investigation and warrants detailed understanding:
- Principle: Rapidly proliferating urothelial cancer cells are exfoliated into the urine. A cytopathologist examines the urine sediment for malignant cells.
- Sensitivity: Overall only ~34% (very insensitive) [3]
- Usually increases with tumour grade: 12% for grade 1, 26% for grade 2, 64% for grade 3 [3]
- Why? Low-grade tumours are well-differentiated → cells look almost normal → hard to identify as malignant. High-grade tumours have marked nuclear anaplasia → easier to spot.
- Specificity: Very high ( > 98%) → therefore any positive cytology should be assumed to represent malignancy (either urothelial malignancy or CIS) [1][3]
- Role: mainly as adjunct to cystoscopy at diagnosis and for detection of recurrent tumours [3]
- Practical tips [3]:
- Send as much volume as possible
- Must be sent fresh (cells degrade rapidly)
- Avoid first early morning urine (too many degenerated epithelial cells from overnight stasis)
- Usually advise sending the 2nd void in the morning on 3 consecutive days [3]
- Results: reported as normal, atypical, suspicious, or malignant [5]
- Note: atypical cytology can occur in UTI → repeat in a few weeks after treatment [5]
- Can detect high-grade urothelial carcinoma / CIS before a gross lesion becomes noticeable on cystoscopy — this is its greatest strength [5]
- FISH (fluorescence in situ hybridisation) for aneuploidy of chromosomes 3, 7, 17 and 9p21 deletion
- Higher sensitivity than cytology for detecting early recurrence
- Rarely done in HK [3]
- Other markers: NMP22, BTA stat — not widely used due to variable sensitivity/specificity
Cytology vs Cystoscopy
Think of urine cytology as a "screening net" with very few false positives (high specificity) but many false negatives (low sensitivity). It cannot replace cystoscopy. Its main role is: (1) detecting CIS (which is flat and may be missed on standard cystoscopy), and (2) surveillance after treatment. If cytology is positive but cystoscopy is negative, you must hunt for CIS (random biopsies, fluorescence) or upper tract disease (CTU, URS) [3].
C. Cystoscopy — The Gold Standard for Lower Urinary Tract [1][2][3][5]
"Cystoscopy" literally means "cysto-" (bladder) + "-scopy" (to look at). It is the direct visualisation of the bladder interior using an endoscope passed through the urethra.
| Type | Setting | Anaesthesia | Purpose |
|---|---|---|---|
| Flexible cystoscopy | Office/outpatient (16 Fr scope) | Local anaesthetic gel | Initial diagnostic visualisation; surveillance |
| Rigid cystoscopy (resectoscope) | Operating theatre | GA / regional | TURBT — resection + biopsy; therapeutic |
- Flexible cystoscopy is performed first as the diagnostic step
- ± Fluorescence (photodynamic diagnosis, PDD): hexaminolevulinate (HAL) is instilled intravesically 1 hour before → preferentially taken up by neoplastic cells → fluoresces pink under blue light → better detection of papillary tumours and especially CIS which appear as flat velvety lesions invisible under white light [3]
- Also known as blue-light cystoscopy (BLC) or narrow-band imaging (NBI) as an alternative enhancement
- Site of tumour(s) — mapped on a bladder diagram
- Size (cm)
- Number (single vs multiple — multifocality)
- Appearance — papillary vs sessile vs flat
- Mucosal abnormalities elsewhere (erythema, oedema, suspicious patches)
| Appearance | Likely Diagnosis | Significance |
|---|---|---|
| Papillary with narrow stalk | Low-grade non-invasive carcinoma (Ta) | Good prognosis; likely NMIBC [1][3] |
| Large, broad-based, irregular/ulcerated, sessile or nodular | High-grade invasive carcinoma | Suggests MIBC; needs deep biopsy including muscle [1][3] |
| Patchy flat velvety lesions | Carcinoma in situ (CIS) | High-grade, easily missed; poor prognosis if untreated; fluorescence-guided biopsy helps [1][3] |
| No visible tumour but +ve urine cytology | CIS, upper tract CA, or prostatic urethral CA | Requires random bladder biopsies ± fluorescence, upper tract imaging (CTU), URS, prostatic urethra biopsy [3] |
Critical Teaching Point
Cystourethroscopy + biopsy is the GOLD STANDARD for initial diagnosis and staging of bladder cancer [1]. Any visible tumour or suspicious lesion should be either biopsied or resected transurethrally (TURBT) to determine the histology and depth of invasion [1]. Biopsy alone may not determine extent of muscle invasiveness — TURBT with deep resection including detrusor muscle is needed for accurate T-staging.
D. Transurethral Resection of Bladder Tumour (TURBT) — Diagnostic AND Therapeutic [2][3][4][8]
TURBT is the pivotal procedure in bladder cancer management. It serves three simultaneous roles:
| Role | Explanation |
|---|---|
| Diagnostic | Provides tissue for histopathological confirmation of bladder cancer type and grade |
| Staging | Determines depth of invasion (T-stage) — specifically: is muscularis propria invaded? This is the critical question. Imaging may not be accurate for this [3] |
| Therapeutic | Can be curative for NMIBC (complete resection of superficial tumours) [2][3] |
- Examination Under Anaesthesia (EUA): bimanual palpation before and after resection
- Palpable mass before resection that persists after suggests ≥ T3 disease
- Fixed mass → T4b (pelvic sidewall invasion) → unresectable
- Rigid cystoscope (resectoscope) inserted via urethra under GA/regional anaesthesia
- Resection: en-bloc for small exophytic tumours; piecemeal for larger ones
- Adjuncts:
- ± Biopsy of other bladder regions: prostatic urethra (if bladder neck tumour, CIS, or +ve cytology without visible bladder mass), random biopsies of normal/abnormal-appearing urothelium [3]
This is a critical concept frequently tested in exams.
Performed 4–6 weeks after initial staging TURBT [4][8]
- High-grade / CIS: significant risk of upstaging — residual disease found in 20–30% of cases who had "complete resection" at first TURBT [2]
- Absence of detrusor muscle in initial TURBT specimen — if no muscle is present in the specimen, you cannot determine whether the tumour is T1 (lamina propria only) or ≥T2 (muscle-invasive). You must re-resect to get muscle [4][8]
- Incomplete initial resection [4][8]
Why is this so important? Because if you understage a T2 tumour as T1, you will treat it conservatively (intravesical BCG) when it actually needs radical cystectomy. The 2nd look TURBT catches these "upstaging" errors.
| Complication | Mechanism |
|---|---|
| Bleeding | Highly vascular tumour bed; raw resection surface |
| Infection | Urinary tract instrumentation breaches mucosal barrier |
| Recurrence | Incomplete resection; field cancerisation → new tumours at other sites |
| TUR syndrome | Absorption of hypotonic irrigation fluid (glycine) → dilutional hyponatraemia, fluid overload (same as in TURP) |
| Obturator kick | Diathermy current on lateral bladder wall stimulates the nearby obturator nerve → sudden powerful adductor spasm of the ipsilateral leg → increased risk of bladder perforation [3] |
| Bladder perforation | Due to obturator kick or deep resection; may be intra- or extra-peritoneal |
E. Upper Urinary Tract Imaging [1][2][3][5]
Upper tract imaging is essential because of the field cancerisation concept — ~3% of bladder cancer patients have synchronous upper tract tumours [3], and the entire urothelium must be surveyed.
| Phase | Timing | What It Shows | Relevance |
|---|---|---|---|
| Non-contrast phase | Before contrast | Calculi, calcification, baseline density | Detect stones; identify calcified masses |
| Arterial/corticomedullary phase | ~30s post-contrast | Renal parenchymal enhancement; vascular anatomy | LN involvement / metastasis detection [2]; renal mass characterisation |
| Nephrographic phase | ~90s post-contrast | Uniform renal parenchymal enhancement | Best for detecting renal masses |
| Delayed/excretory phase | 3–5 minutes post-contrast | Contrast fills collecting system, ureters, bladder | Look for filling defects along entire urinary tract — tumour masses appear as filling defects within the contrast-opacified lumen [2] |
- Bladder: filling defect in bladder lumen (soft-tissue mass protruding into contrast-filled bladder); misses small tumours < 1 cm, particularly those in the trigone or dome [1]; cannot differentiate depth of bladder wall invasion [1]
- Upper tract: filling defect in renal pelvis or ureter → suspect urothelial CA
- Extravesical extension: perivesical fat stranding, soft tissue extending beyond bladder wall (~80% accurate for detecting extravesical extension) [3]
- Lymph nodes: enlarged pelvic or retroperitoneal nodes (68% false positive rate for nodal involvement — enlarged nodes may be reactive, not metastatic) [3]
- Hydronephrosis/hydroureter: suggests ureteric obstruction by tumour
- Distant metastases: liver lesions, lung base nodules, bony lesions
CT should include BOTH abdomen and pelvis and BOTH with and without contrast [1].
Timing: ideally done before TURBT as resection will alter the radiological appearance (post-operative oedema, haematoma) [3].
- Largely replaced by CTU [5]
- IV contrast with fluoroscopy → delineate urinary system anatomy after 15–20 min
- Advantages: economic, good for upper tract lesions
- Disadvantages: not sensitive for renal lesions < 3 cm, cannot provide coronal/sagittal imaging, cannot detect small bladder lesions [5]
- Findings: CA bladder appears as a filling defect in the bladder [5]; hydroureter/hydronephrosis in obstruction
- Classical urographic finding of upper tract TCC: meniscus-shaped ureteral filling defect known as the "Goblet" sign — produced by contrast being trapped in the fronds of a papillary tumour [1]
- Advantages: No radiation, no contrast, bedside, useful in pregnancy
- Can detect: soft tissue mass in bladder (if large), hydronephrosis, renal parenchymal disease, prostate size
- CANNOT determine depth of invasion, extravesical extension, or nodal status [1]
- Disadvantages: insensitive for small tumours and ureteric lesions (only proximal and distal ureter visualised) [3][5]
- Indicated in patients with allergy to iodinated contrast [1]
- Advantages: no irradiation; may be superior to CTU for superficial and multiple tumours, extravesical tumour extension and surrounding organ invasion [3]
- Disadvantages: expensive, image inferior to CT for mobile organs (kidney), cannot be used in claustrophobic patients or patients with pacemakers or other metallic foreign bodies [1]; less able to detect smaller urothelial lesions and non-obstructing stones [7]
- Invasive: injection of contrast by catheterisation of lower ureter via cystoscopy
- Indicated in patients with insufficient renal function to excrete IV contrast [1][7]
- Classical finding: "Goblet" sign — meniscus-shaped ureteral filling defect in upper tract TCC [1]
- Largely supplanted by CTU but still useful when CTU/IVU contraindicated
- Direct visualisation of ureter and renal pelvis with flexible/rigid ureteroscope
- Allows direct biopsy and brush cytology (90% sensitivity, but invasive and may bleed/perforate) [5]
- Indicated when upper tract imaging is indeterminate, or when cytology is positive but no bladder/upper tract lesion found on imaging
Once bladder cancer is confirmed histologically, staging workup determines the extent of disease. The level of staging depends on whether NMIBC or MIBC:
| Investigation | Purpose | When to Order |
|---|---|---|
| CXR | Lung metastasis | All patients (minimum); CT thorax preferred if MIBC or other mets present [2][3] |
| CT abdomen and pelvis (with contrast) | LN involvement, local extension, liver metastasis | All MIBC; may already be obtained as CTU [2][3] |
| Radionuclide bone scan | Bone metastasis | Usually only in symptomatic patients (bone pain) or invasive disease [2][3] |
| PET-CT | Metastasis detection | FDG not sensitive for bladder CA (excreted in urine → high background); prefer 11C-acetate [3][8] |
PET-CT Detail [3][8]
- Standard 18F-FDG PET is problematic in urothelial cancer because FDG is renally excreted → accumulates in the bladder → obscures the primary tumour
- 11C-acetate PET is preferred for bladder/renal cancer as it is not renally excreted and is taken up by tumour cells [3][8]
- Not routinely used in HK; reserved for equivocal cases
| Investigation | Sensitivity for Bladder Tumour | Can Stage Depth? | Can Detect Upper Tract? | Limitations |
|---|---|---|---|---|
| Urine cytology | Low (34% overall; ↑ with grade) | No | Indirect (+ cytology → suspect) | Very high specificity ( > 98%) but low sensitivity |
| Flexible cystoscopy | Very high for visible tumours | No (cannot assess depth) | No | May miss CIS (flat); needs fluorescence/NBI |
| TURBT | Gold standard — provides tissue | Yes (if muscle included) | No | Invasive; risk of perforation, TUR syndrome |
| CTU | Moderate (~80% for extravesical) | Limited | Yes (filling defects) | Misses tumours < 1 cm; 68% FP for nodes; radiation |
| IVU | Low (60–85% for large tumours) | No | Yes (Goblet sign) | Largely replaced by CTU |
| USG | Low (large tumours only) | No | Hydronephrosis only | Cannot assess invasion/nodes |
| MRU | Moderate–good | Better than CT for local staging | Yes | Expensive; limited in claustrophobia/pacemakers |
| Bone scan | High for bony mets | N/A | N/A | Only for symptomatic/invasive disease |
| PET-CT | Variable; FDG poor for bladder | N/A | Yes | FDG excreted in urine; prefer 11C-acetate |
AJCC 8th Edition TNM Staging [3][4]:
| Stage | Description | NMIBC vs MIBC |
|---|---|---|
| Ta | Non-invasive papillary carcinoma, no invasion to lamina propria [4] | NMIBC |
| Tis | Flat, high-grade lesion (CIS) [4] | NMIBC |
| T1 | Tumour invades the lamina propria but not the muscle [4] | NMIBC |
| T2 | Tumour invades the muscularis propria (muscle layer) [4] | MIBC |
| T2a | Invades superficial muscle (inner half) [4] | MIBC |
| T2b | Invades deep muscle (outer half) [4] | MIBC |
| T3 | Tumour invades the perivesical fat [4] | MIBC |
| T3a | Microscopic invasion of perivesical fat [4] | MIBC |
| T3b | Macroscopic (visible or palpable) invasion of perivesical fat [4] | MIBC |
| T4 | Tumour invades surrounding organs [4] | MIBC |
| T4a | Invades prostate, uterus, or vagina [4] | MIBC |
| T4b | Invades pelvic wall or abdominal wall [4] | MIBC |
- Papillary urothelial neoplasm of low malignant potential (PUNLMP) — very slow growing [4]
- Low-grade papillary urothelial carcinoma [4]
- High-grade papillary urothelial carcinoma [4]
Clinical significance [4]:
- Low-grade tumours tend to recur but rarely progress to muscle invasion
- High-grade tumours and CIS have a higher risk of progression and metastasis
High Yield: CIS is by definition high-grade intraepithelial neoplasm without invasion into subepithelial connective tissue. Despite being "superficial" (Tis), it has very poor prognosis if untreated because it consists of high-grade cells with a high propensity for progression to MIBC [1][3].
High Yield Summary
Diagnosis of bladder cancer is histopathological — no single test confirms it; tissue from cystoscopy/TURBT is required.
Diagnostic algorithm: Haematuria workup → urinalysis + cytology → upper tract imaging (CTU preferred) → flexible cystoscopy → TURBT (diagnosis + staging + therapy).
Urine cytology: Low sensitivity (34%) but very high specificity ( > 98%) → any positive = assume malignancy. Best for high-grade/CIS. Send fresh, 2nd morning void x3 days.
Cystoscopy is the gold standard for lower tract; fluorescence/PDD improves CIS detection. Document site, size, number, appearance.
TURBT = pivotal procedure: diagnostic (histology), staging (depth — must include detrusor muscle), and therapeutic (curative for NMIBC).
2nd look TURBT (4–6 weeks): indicated for (1) high-grade/CIS, (2) no detrusor muscle in initial specimen, (3) incomplete initial resection — residual disease in 20–30%.
CTU: preferred upper tract imaging; delayed phase (3–5 min) for filling defects; misses tumours < 1 cm; ~80% accurate for extravesical extension; 68% FP for nodal involvement.
IVU: largely replaced; "Goblet sign" = classic upper tract TCC finding.
Staging Ix for MIBC: CXR/CT thorax, CT A+P, bone scan (if symptomatic); PET-CT with 11C-acetate (FDG not sensitive for bladder CA).
Staging: Ta/Tis/T1 = NMIBC; ≥T2 = MIBC. Grading: PUNLMP → low-grade → high-grade. Low-grade recurs but rarely progresses; high-grade/CIS progresses and metastasises.
Active Recall - Bladder Cancer Dx Criteria, Algorithm and Investigations
References
[1] Senior notes: felixlai.md (Urothelial bladder cancer section — Diagnosis, Radiological tests) [2] Senior notes: maxim.md (Bladder cancer section — Investigations, TURBT, Staging) [3] Senior notes: Ryan Ho Urogenital.pdf (Section 7.4.1 Bladder Cancer, pp. 152–156) [4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 21–24) [5] Senior notes: Ryan Ho Fundamentals.pdf (Haematuria approach — Investigations, pp. 343–345) [7] Senior notes: felixlai.md (Haematuria section — Radiological tests, Diagnosis) [8] Senior notes: Ryan Ho Diagnostic Radiology.pdf (PET/CT section, p. 74)
Management of Bladder Cancer
The entire management of bladder cancer pivots on one question: Has the tumour invaded the muscularis propria (detrusor muscle)?
- NMIBC (Tis, Ta, T1) → manage with TURBT ± intravesical therapy + lifelong surveillance
- MIBC (≥ T2, up to T4a) → radical cystectomy ± neoadjuvant chemotherapy (or bladder-preserving multimodality therapy)
- Metastatic / unresectable (T4b or M1) → systemic therapy (chemotherapy, immunotherapy, targeted therapy)
A second universal principle: Smoking cessation for ALL patients [3] — smoking is the #1 risk factor and continued smoking increases recurrence, progression, and mortality even after treatment.
1. Management of Non-Muscle-Invasive Bladder Cancer (NMIBC)
NMIBC accounts for ~70–80% of bladder cancers at presentation [3]. The approach is: TURBT (curative intent) → risk stratify → adjuvant intravesical therapy → lifelong surveillance.
1.1 TURBT — The Foundation of NMIBC Treatment [1][2][3][4]
TURBT is simultaneously diagnostic, staging, and therapeutic for NMIBC. (The procedure details were covered in the Diagnostics section; here we focus on its therapeutic role.)
| Aspect | Detail |
|---|---|
| Goal | Complete, visible resection of ALL tumour tissue + underlying detrusor muscle |
| Curative potential | TURBT alone can be curative for NMIBC if complete resection is achieved [2][3] |
| Technique | En-bloc for small exophytic lesions; piecemeal for larger ones [3] |
| Must include | Muscularis propria in the specimen — to determine if invasion is present [3] |
| Adjunct | Fluorescence-guided resection (blue-light cystoscopy) for better tumour detection [3] |
Staging TURBT + immediate post-op instillation of mitomycin C (reduce tumour cells implantation and recurrence) [4]
| Property | Detail |
|---|---|
| Drug | Mitomycin C (MMC) — "mito-" = thread (refers to DNA crosslinking) |
| Class | Cytotoxic alkylating agent — directly crosslinks DNA → prevents cell replication → kills residual cancer cells [2] |
| Timing | Immediate post-op — ideally within 6–24 hours of TURBT [3] |
| Mechanism of benefit | Tumour cells are shed during TURBT and can implant on the raw, denuded urothelium. Immediate MMC kills these free-floating cells before implantation occurs [4] |
| Effect | Reduces recurrence by ~30% [3] — but does NOT reduce progression rate (cf. BCG) [2] |
| Indication | Low risk and intermediate risk NMIBC; also given empirically in all NMIBC if no contraindication [1][3] |
| Contraindication | Suspected or confirmed muscle invasion (do NOT give if MIBC likely — wait for histology); suspected bladder perforation |
| Side effects | Chemical cystitis, skin rash [1][2] |
Why Mitomycin C Immediately, Not BCG?
Immediate post-op BCG is contraindicated because BCG is a live attenuated organism (Mycobacterium bovis). If instilled into a freshly resected, raw bladder, it can enter the bloodstream through exposed vessels → BCG sepsis (a life-threatening systemic mycobacterial infection). Mitomycin C, being a chemical agent, does not carry this risk [2].
Performed 4–6 weeks after initial staging TURBT [4]
Indications [4]:
- High-grade / CIS: significant risk of upstaging
- Absence of detrusor muscle in initial TURBT specimen
- Incomplete initial resection
Why? Residual disease is found in 20–30% of cases who had apparently "complete resection" at the first TURBT [2]. Understaging a T2 tumour as T1 → patient receives BCG instead of radical cystectomy → disease progresses → poor outcome.
After TURBT, pathology determines the risk group, which dictates adjuvant treatment:
| Risk Group | Definition | Risk of Progression | Recommended Treatment |
|---|---|---|---|
| Low | Primary, solitary, low-grade Ta, < 3 cm, no CIS [1][3] | 0–4% | TURBT + single immediate post-op intravesical MMC [1][3] |
| Intermediate | All tumours not meeting low or high risk criteria [1] | 10–15% | TURBT + post-op MMC + 1 year full-dose intravesical BCG or chemotherapy [1][3] |
| High | ANY of: T1, high-grade Ta, CIS, or multiple + recurrent + > 3 cm low-grade tumour [1][3] | 30–40% | TURBT + post-op MMC + 2nd look TURBT + intravesical BCG × 1–3 years; consider radical cystectomy if very high risk [1][3] |
| BCG-refractory | Tumour recurs/persists despite adequate BCG | Very high | Radical cystectomy (or bladder-preserving strategies if unfit) [3] |
1.3 Intravesical Therapy — BCG vs Chemotherapy
Intravesical Bacillus Calmette-Guérin (BCG): given 4–6 weeks after staging TURBT for high-risk NMIBC to reduce risk of recurrence and progression [4]
BCG is one of the most fascinating treatments in oncology — a tuberculosis vaccine repurposed as cancer immunotherapy.
| Property | Detail |
|---|---|
| What is it? | Live attenuated vaccine made from Mycobacterium bovis [1][2] |
| Mechanism | Triggers non-specific cytokine-mediated local immune response [1] — BCG organisms attach to the urothelium → internalized by urothelial cells → presented to immune cells → massive influx of CD4+ T cells, macrophages, NK cells → cytokine storm (IL-2, TNF-α, IFN-γ) → immune-mediated destruction of residual cancer cells + increased tumour antigen expression [5] |
| Route | Instillation of BCG + normal saline into bladder via urethral catheter → retained for 2 hours → voided [3] |
| Timing | Started ≥ 2–3 weeks (4–6 weeks per lecture slides) after TURBT [3][4] — must allow mucosal healing to prevent systemic absorption |
| Regimen (Induction) | Weekly × 6 weeks (Lamm's induction) [1][2][3] |
| Regimen (Maintenance) | Weekly × 3 weeks at 3, 6, 12 months (intermediate risk — total 1 year) [1][2] |
| Weekly × 3 weeks at 3, 6, 12, 18, 24, 30, 36 months (high risk — total 3 years) [1][3] | |
| PWH regimen: induction (weekly × 6) + maintenance (weekly × 3 at 3mo, × 3 at 6mo, × 3 at 12mo) — 15 doses for 1 year total [2] | |
| Effect | Reduces both recurrence AND progression rate (4–27% reduction in progression) [2][3] — this is the key difference from MMC, which reduces recurrence only |
| Indication | First-line treatment for CIS [2]; high-risk and intermediate-risk NMIBC |
Contraindications for BCG [3]:
- < 2 weeks after TURBT (mucosal not healed → risk of systemic absorption)
- Gross haematuria (raw surface → BCG enters bloodstream)
- After traumatic catheterisation
- Symptomatic UTI (active infection → immunocompromised state)
- Immunosuppressed patients (live vaccine)
| Category | Side Effect | Mechanism |
|---|---|---|
| Local | Cystitis (frequency, urgency, dysuria), prostatitis, epididymo-orchitis | Local inflammatory response to BCG organisms |
| Systemic | BCG sepsis, pneumonitis, hepatitis, arthritis, fever, malaise | Systemic dissemination of live organisms or systemic immune activation |
Management of BCG complications: Localized symptoms usually self-limiting; systemic BCG sepsis is a medical emergency → treat with anti-TB drugs (isoniazid, rifampicin, ethambutol) + corticosteroids [2][3].
BCG Compliance Issue
The maintenance regimen is troublesome — 15 doses over 1 year (PWH) or up to 27 doses over 3 years (full EAU). Compliance is a significant problem. Patients often drop out due to irritative symptoms. Counsel patients carefully about the importance of completing the course — incomplete BCG is associated with higher recurrence and progression [2].
| Property | Detail |
|---|---|
| Drug | Mitomycin C (most common); gemcitabine (alternative) |
| Mechanism | Alkylating agent → DNA crosslinking → direct cytotoxicity to cancer cells |
| Single post-op instillation | Standard for low-risk NMIBC; given within 6–24h of TURBT |
| Maintenance therapy | For 1 year in intermediate-risk NMIBC (rarely done in HK) [3] |
| Effect | Reduces recurrence but NOT progression (unlike BCG) [2] |
| Side effects | Chemical cystitis, palmar rash (contact dermatitis) [1][2] |
| Feature | BCG | Mitomycin C |
|---|---|---|
| Mechanism | Immunotherapy (immune activation) | Chemotherapy (direct cytotoxicity) |
| Reduces recurrence | Yes | Yes |
| Reduces progression | Yes | No |
| Use for CIS | First-line | Not first-line |
| Timing after TURBT | ≥ 2–6 weeks (mucosal healing needed) | Immediate (within 24h) |
| Side effects | Irritative LUTS, BCG sepsis risk | Chemical cystitis, rash |
| Compliance | Poor (long regimen) | Better (single dose or short course) |
Bladder cancer has a notorious 70% lifetime risk of tumour recurrence [3]. Surveillance is lifelong.
| Risk Group | Surveillance Cystoscopy Schedule | Additional |
|---|---|---|
| Low risk | 3 months, 12 months, then yearly × 5 years [2] | — |
| High risk | Every 3 months × 2 years, then every 6 months × 3 years, then yearly (can be lifelong) [2] | + Yearly upper tract imaging (CTU) + urine cytology [2] |
Why lifelong surveillance? Field cancerisation means new tumours can arise anywhere in the urothelium at any time. A single negative cystoscopy does not mean the patient is cured.
2. Management of Muscle-Invasive Bladder Cancer (MIBC)
MIBC (pT2–T4a) is an aggressive disease — > 90% 2-year mortality if untreated [3]. However, with appropriate treatment, 5-year survival > 50% after cystectomy [3].
2.1 Radical Cystectomy (RC) — Gold Standard for MIBC [2][3][4]
Neoadjuvant chemotherapy + Radical cystectomy: open / laparoscopic / robotic [4]
Radical cystectomy: bladder + bilateral pelvic LN dissection (external iliac, internal iliac, obturator nodes) + adjacent organs [2]
| Sex | Structures Removed |
|---|---|
| Male | Bladder, prostate, seminal vesicles ± urethra (cystoprostatectomy) + regional LNs [2][3] |
| Female | Bladder, uterus, bilateral salpingo-oophorectomy (HBSO), part of vagina ± urethra (anterior exenteration) + distal ureters + regional LNs [2][3] |
Why pelvic lymph node dissection? Pelvic LN dissection offers survival benefit (cf. CA prostate where LND benefit is debatable) because microscopic metastasis is common in bladder cancer [2]. Extended LND (up to common iliac and presacral nodes) improves staging accuracy and may improve survival.
- Very high-risk NMIBC (BCG-refractory, T1HG with multiple adverse features)
- Resectable MIBC: T2–T4a [3]
- T4b (pelvic wall or abdominal wall invasion) — this is unresectable [3]
- Medically unfit for major surgery (significant cardiac, pulmonary, or other comorbidities)
- Patient declines surgery (offer bladder-preserving alternatives)
| Technique | Detail |
|---|---|
| Open | Traditional approach; best established evidence |
| Laparoscopic | Less blood loss, faster recovery; similar oncological outcomes |
| Robotic | Increasingly used; ergonomic advantages for surgeon; similar oncological outcomes in experienced centres |
In carefully selected individuals (organ-confined disease without tumour in prostate, urethra, or bladder neck):
- Males: prostate-sparing, capsule-sparing, seminal vesicle–sparing, nerve-sparing cystectomy
- Females: preservation of neurovascular bundle, vagina, or uterus
- These reduce sexual dysfunction and urinary incontinence but must not compromise oncological safety
2.2 Urinary Diversion After Radical Cystectomy [3]
Once the bladder is removed, urine must be diverted. There are two broad categories:
| Type | Description | Pros / Cons |
|---|---|---|
| Ureterocutaneostomy | Ureters brought directly to abdominal wall surface | Simple; but ↓calibre of ureters → ↑risk of stenosis [3] |
| Ileal conduit (most common in HK) [3] | Ureters implanted into a short isolated segment (~15–20 cm) of ileum (or colon) → brought to abdominal surface as a stoma | Majority of urinary diversions in HK [3]; lower risk of ureteroileal stricture than ureterocutaneostomy; requires external urostomy bag |
| Type | Description | Pros / Cons |
|---|---|---|
| Continent cutaneous reservoir (e.g., Indiana pouch) | Bowel segment fashioned into an internal reservoir → catheterisable stoma on abdominal wall | No external bag; requires self-catheterisation every 4–6 hours |
| Orthotopic neobladder (e.g., Studer, Hautmann) | Bowel segment fashioned into a reservoir → anastomosed to the urethra | Most physiological — patient voids via the urethra; requires intact external sphincter and no tumour at urethra/bladder neck; risk of nocturnal incontinence (neobladder lacks detrusor contraction — voiding by Valsalva/abdominal straining) |
Why Use Bowel for Urinary Diversion?
Bowel is the only readily available tubular tissue in the body that can be refashioned into a conduit or reservoir. Ileum is most commonly used because it has a reliable mesentery, is relatively easy to mobilize, and produces less mucus than colon. However, using bowel for urinary diversion can cause metabolic complications: hyperchloraemic metabolic acidosis (bowel mucosa reabsorbs Cl⁻ and NH₄⁺ from urine, exchanges for HCO₃⁻) and vitamin B12 deficiency (terminal ileum is the site of B12 absorption — resection removes this).
2.3 Neoadjuvant and Adjuvant Chemotherapy [3][4]
Neoadjuvant chemotherapy + Radical cystectomy [4]
| Property | Detail |
|---|---|
| Regimen | Cisplatin-based combination therapy (e.g., GC = gemcitabine + cisplatin; MVAC = methotrexate + vinblastine + doxorubicin + cisplatin; PGC = paclitaxel + gemcitabine + cisplatin) [3] |
| Timing | Given before radical cystectomy (typically 3–4 cycles) |
| Rationale | (1) Downstage the tumour → improve resectability; (2) Treat micrometastatic disease early (before surgery selects for resistant clones); (3) Patients tolerate chemo better pre-op than post-op (better renal function, better performance status) |
| Indication | Recommended for all patients undergoing curative RC [3] |
| Survival benefit | ~5% absolute improvement in 5-year overall survival |
| Prerequisite | Adequate renal function (cisplatin is nephrotoxic — requires GFR > 60 mL/min); if cisplatin-ineligible, role of neoadjuvant chemo is less clear |
| Property | Detail |
|---|---|
| Timing | Given after radical cystectomy |
| Indication | Role unclear — may be offered to pT3+ or N1+ patients who did NOT receive neoadjuvant therapy [3] |
| Rationale | Treats residual micrometastatic disease identified on final pathology |
| Limitation | Post-operative renal function may be impaired (single kidney with ureteric reimplantation); patients may not tolerate cisplatin post-op |
Radiotherapy for frail patient not fit for surgery [4]
This is the alternative to radical cystectomy for patients who wish to keep their bladder or who are unfit for major surgery.
| Property | Detail |
|---|---|
| Components | Maximal TURBT (resect ALL visible tumour) + chemoradiation with platinum-based chemotherapy (e.g., cisplatin, or mitomycin C + 5-FU) [3] |
| Also called | Trimodality therapy (TMT) = maximal TURBT + chemotherapy + radiation |
| Indications [3] | (1) Alternative to RC in selected, well-informed patients who wish to preserve sexual function / bladder; (2) In place of RC in patients with significant comorbidities where RC is not an option |
| Prefer RC over TMT if [3] | Presence of CIS (diffuse field disease → poor response to RT); upper tract obstruction (suggests advanced local disease); IBD (radiation contraindicated); severe storage LUTS; previous extensive pelvic surgery or RT |
| Outcome | 5-year overall survival 36–74% (inferior to RC, but no direct RCT comparison exists) [3] |
Why is it inferior? Radiation cannot adequately treat microscopic disease throughout the entire urothelium (field cancerisation), and residual CIS/multifocal disease in the bladder remnant leads to local recurrence. However, it preserves quality of life (no stoma, preserved sexual function).
3. Management of Metastatic / Unresectable Bladder Cancer [1][3][4]
Metastatic bladder cancer (any T, N+, M1) or unresectable disease (T4b) is incurable with surgery alone. Management is systemic.
Systemic chemotherapy: cisplatin or carboplatin-based [4]
| Regimen | Components | Notes |
|---|---|---|
| GC | Gemcitabine + Cisplatin | Most commonly used first-line; better tolerated than MVAC [3] |
| MVAC | Methotrexate + Vinblastine + Doxorubicin + Cisplatin | Historical standard; higher toxicity; ± G-CSF support [3] |
| PGC | Paclitaxel + Gemcitabine + Cisplatin | Triplet; used in selected fit patients [3] |
| Carboplatin-based | Gemcitabine + Carboplatin | For cisplatin-ineligible patients (GFR < 60, poor performance status, hearing loss, neuropathy, heart failure) [3] |
Immunotherapy: Immune checkpoint inhibitors (e.g., pembrolizumab) [4]
| Agent | Target | Notes |
|---|---|---|
| Pembrolizumab | PD-1 inhibitor | FDA-approved for platinum-refractory advanced urothelial CA; also first-line for cisplatin-ineligible patients with PD-L1 high expression [3][4] |
| Atezolizumab | PD-L1 inhibitor | Second-line after platinum failure [3] |
| Nivolumab | PD-1 inhibitor | Adjuvant setting post-RC for high-risk MIBC (EAU 2024); also second-line metastatic |
| Avelumab | PD-L1 inhibitor | Maintenance after first-line platinum-based chemo (switch maintenance strategy) — significant survival benefit |
Why do checkpoint inhibitors work in bladder cancer? Urothelial carcinoma has a high tumour mutational burden (TMB) — due to carcinogen exposure (smoking, chemicals) → many neoantigens → but the tumour upregulates PD-L1 to evade immune detection. Blocking PD-1/PD-L1 "releases the brakes" on T-cell-mediated anti-tumour immunity.
Target therapy: FGFR inhibitors are used for specific genetic alterations [4]
| Agent | Target | Indication |
|---|---|---|
| Erdafitinib | FGFR2/3 inhibitor | For patients with FGFR3 mutations or FGFR2/3 fusions — typically in the low-grade papillary pathway; used in platinum-refractory setting [4] |
Why FGFR? Recall from the molecular pathogenesis section: the low-grade papillary pathway is driven by FGFR3 activating mutations (~70% of low-grade tumours). Erdafitinib directly inhibits this driver → tumour regression. This is a classic example of precision oncology.
| Agent | Role |
|---|---|
| Vinflunine | 2nd-line chemotherapy (approved in Europe, rarely used) |
| Enfortumab vedotin | Antibody-drug conjugate targeting Nectin-4; approved for platinum- and IO-refractory urothelial CA (3rd line); significant survival benefit |
| Sacituzumab govitecan | Antibody-drug conjugate targeting Trop-2; emerging evidence |
| Stage | Prognosis |
|---|---|
| NMIBC | 10–20% progress to MIBC; 70% lifetime risk of tumour recurrence → lifelong surveillance mandatory |
| MIBC (untreated) | > 90% 2-year mortality |
| MIBC (after cystectomy) | 5-year survival > 50% |
| Metastatic (1st-line chemo) | Median survival ~14–15 months; improved with immunotherapy maintenance |
| Stage | Treatment |
|---|---|
| Low-risk NMIBC | TURBT + single immediate post-op MMC [1][3][4] |
| Intermediate-risk NMIBC | TURBT + post-op MMC + 1-year intravesical BCG or chemo [1][3] |
| High-risk NMIBC | TURBT + post-op MMC + 2nd look TURBT + intravesical BCG × 1–3 years; consider RC if very high risk [1][3][4] |
| CIS (first-line) | Intravesical BCG (first-line treatment for CIS) [2] |
| BCG-refractory | Radical cystectomy [3] |
| MIBC (T2–T4a) | Neoadjuvant cisplatin-based chemo + radical cystectomy + pelvic LND + urinary diversion [3][4] |
| MIBC (unfit for surgery) | Bladder-preserving: maximal TURBT + chemoradiation [3][4] |
| Metastatic | 1st line: cisplatin/carboplatin-based chemo → maintenance avelumab; 2nd line: pembrolizumab/atezolizumab; FGFR inhibitors if FGFR-altered [3][4] |
High Yield Summary
NMIBC Management (Tis/Ta/T1):
- TURBT is the cornerstone — diagnostic, staging, AND therapeutic
- Immediate post-op intravesical mitomycin C for ALL NMIBC (reduces recurrence by ~30%, NOT progression; immediate because it prevents tumour cell implantation)
- Risk stratify: Low → MMC only; Intermediate → BCG or chemo × 1 year; High → BCG × 1–3 years ± 2nd look TURBT ± radical cystectomy
- BCG is first-line for CIS and reduces BOTH recurrence AND progression (unlike MMC which only reduces recurrence)
- BCG is a live attenuated vaccine (M. bovis) → NEVER give immediately post-TURBT (risk of BCG sepsis)
- BCG regimen: induction weekly × 6 → maintenance weekly × 3 at regular intervals
- BCG side effects: irritative LUTS (local), BCG sepsis (systemic) → treat with anti-TB drugs
- 2nd look TURBT at 4–6 weeks if: (1) high-grade/CIS, (2) no detrusor in specimen, (3) incomplete resection
- Surveillance is LIFELONG: field cancerisation → 70% lifetime recurrence risk
MIBC Management (T2–T4a):
- Neoadjuvant cisplatin-based chemo + Radical cystectomy (open/lap/robotic) + pelvic LND + urinary diversion (most commonly ileal conduit in HK)
- RC removes: M — bladder + prostate + seminal vesicles ± urethra; F — bladder + uterus + HBSO + part of vagina ± urethra
- Pelvic LND provides survival benefit (microscopic mets common)
- Bladder-preserving TMT (maximal TURBT + chemoRT) for unfit/patient preference
Metastatic (T4b/M1):
- 1st line: cisplatin-based chemo (GC or MVAC); carboplatin if cisplatin-ineligible
- 2nd line: immune checkpoint inhibitors (pembrolizumab, atezolizumab)
- Targeted: FGFR inhibitors (erdafitinib) for FGFR-altered tumours
- Maintenance avelumab after 1st-line chemo
- Antibody-drug conjugates (enfortumab vedotin) for refractory disease
T4b = unresectable (pelvic wall/abdominal wall invasion)
Active Recall - Bladder Cancer Management
[1] Senior notes: felixlai.md (Urothelial bladder cancer section — Treatment, Risk stratification) [2] Senior notes: maxim.md (Bladder cancer section — Management NMIBC, Management MIBC) [3] Senior notes: Ryan Ho Urogenital.pdf (Section 7.4.1 Bladder Cancer — Approach to Mx, TURBT, Intravesical therapy, Radical cystectomy, pp. 155–158) [4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 24–25) [5] Senior notes: Ryan Ho Fundamentals.pdf (Management of urinary tumours, p. 345)
Complications in bladder cancer arise from three distinct sources:
- The disease itself — local progression and distant metastasis
- Treatment — TURBT, intravesical therapy, radical cystectomy, chemotherapy, radiotherapy, immunotherapy
- Surveillance burden — lifelong cystoscopy and its attendant morbidity
Understanding the complications from first principles means asking: "What does the tumour physically do as it grows?" and "What are we damaging when we treat it?"
1. Complications of the Disease Itself
| Complication | Mechanism (First Principles) | Clinical Presentation |
|---|---|---|
| Hydronephrosis and hydroureter [1] | Invasive bladder tumour at or near the ureteric orifice/trigone obstructs the distal ureter → urine cannot drain → back-pressure dilates the ureter and renal pelvis | Flank pain (renal capsule stretch), silent renal impairment (bilateral obstruction → post-renal AKI), palpable loin mass [1][6] |
| Acute urinary retention | Large tumour mass or blood clots (from tumour haemorrhage) physically block the bladder neck or urethra | Inability to void, suprapubic pain and distension, overflow incontinence |
| Chronic haematuria → iron deficiency anaemia | Persistent bleeding from friable tumour neovasculature → ongoing urinary blood loss → depletes iron stores | Pallor, fatigue, palpitations, exertional dyspnoea [5] |
| Vesicocolic fistula → pneumaturia [3] | T4a tumour erodes through the bladder wall into the adjacent sigmoid colon/rectum → creates abnormal communication between the bowel and bladder | Pneumaturia (air in urine — pathognomonic), faecaluria (faecal particles in urine), recurrent polymicrobial UTIs [3] |
| Vesicovaginal fistula → incontinence [3] | T4a tumour erodes into the vagina → continuous leak of urine through the vagina | Continuous vaginal discharge of urine, irritation, recurrent UTI [3] |
| Bladder outlet obstruction | Tumour at bladder neck or encasing the prostatic urethra | Obstructive LUTS (hesitancy, weak stream, incomplete emptying), retention |
| Recurrent UTI | Tumour surface serves as nidus for bacterial colonisation; fistulae allow enteric organisms into the bladder; urinary stasis behind obstruction | Dysuria, frequency, fever; polymicrobial infections (especially if fistula) |
Post-Renal AKI from Bladder Cancer
Invasive bladder tumours can cause distal ureteral obstruction and secondary hydronephrosis [1]. If bilateral (or if the patient has a solitary kidney), this produces post-renal AKI — an obstructive uropathy [6]. This is rapidly reversible if recognised early and treated with percutaneous nephrostomy (PCN) or ureteric stent placement. Prolonged obstruction leads to irreversible tubulointerstitial fibrosis [6].
Common metastatic sites are liver, lung, and bone [1]. Each site produces characteristic complications:
| Metastatic Site | Complications | Mechanism |
|---|---|---|
| Liver | RUQ pain, jaundice, hepatomegaly, coagulopathy, liver failure | Tumour deposits replace hepatic parenchyma → biliary obstruction (intrahepatic) → impaired synthetic function |
| Lung | Dyspnoea, cough, haemoptysis, pleural effusion | Parenchymal tumour nodules → ventilation–perfusion mismatch; pleural metastases → exudative effusion |
| Bone | Bone pain (vertebral, pelvic, long bones), pathological fractures, spinal cord compression, hypercalcaemia | Osteolytic destruction by tumour → structural weakening → fracture; osteoclast activation → calcium release |
| Brain | Headache, seizures, focal neurological deficits, cognitive decline | Mass effect of cerebral metastases → raised intracranial pressure, cortical irritation |
| Lymph nodes | Lower limb oedema, DVT, pelvic pain | Bulky pelvic LN metastases compress iliac veins → venous obstruction; compress lumbosacral plexus → pain |
| Complication | Mechanism |
|---|---|
| Cancer cachexia | Tumour cytokines (TNF-α, IL-6, IL-1) → systemic inflammation → protein catabolism, anorexia, weight loss |
| Venous thromboembolism (DVT/PE) | Trousseau syndrome — malignancy produces tissue factor + cancer procoagulant → activates coagulation cascade → hypercoagulable state; also venous stasis from pelvic mass/immobility |
| Anaemia of chronic disease | Hepcidin upregulation by IL-6 → iron sequestration in macrophages → functional iron deficiency (even without overt bleeding) |
2. Complications of Treatment
Complication of surgery: Transurethral resection of bladder tumor (TURBT) [4]
| Complication | Mechanism | Management |
|---|---|---|
| Bleeding | Resection of highly vascular tumour bed; raw, denuded bladder surface | Usually self-limiting; continuous bladder irrigation (CBI) with normal saline; rarely requires return to OT for diathermy |
| Infection / UTI | Urethral instrumentation breaches mucosal barrier; catheterisation | Prophylactic antibiotics; treat with targeted antibiotics per culture |
| Incomplete resection / Recurrence | Piecemeal resection → no histological proof of clear margins; field cancerisation → new tumours at distant urothelial sites | 2nd look TURBT (4–6 weeks); lifelong surveillance cystoscopy |
| TUR syndrome | Absorption of hypotonic irrigation fluid (glycine 1.5%) through open veins in the resection bed → dilutional hyponatraemia + fluid overload | Manifests as: confusion, nausea, bradycardia, hypertension, visual disturbance, seizures. Treat: stop irrigation, fluid restrict, hypertonic saline if severe symptomatic hyponatraemia. Prevention: use bipolar resectoscope (allows normal saline irrigation) |
| Obturator kick | Diathermy current applied to lateral bladder wall tumours stimulates the nearby obturator nerve (L2–L4) → sudden, powerful adductor spasm of the ipsilateral leg | ↑↑ risk of bladder perforation [3]. Prevention: use bipolar diathermy (reduces current spread), GA with muscle relaxant (paralyses the adductors), or obturator nerve block |
| Bladder perforation | Deep resection through full thickness of bladder wall; exacerbated by obturator kick | Intra-peritoneal perforation → acute abdomen, needs laparotomy; extra-peritoneal → conservative (prolonged catheter drainage). Suspect if irrigant not returning |
TUR Syndrome — The Same Mechanism as TURP
TUR syndrome in TURBT is identical to TUR syndrome in TURP (transurethral resection of prostate). Both involve absorption of hypotonic irrigation fluid through open veins. The key difference is that TURBT resection beds are usually smaller, so TUR syndrome is less common than in TURP, but it still occurs — especially with prolonged resection times and large tumours.
2.2 Complications of Intravesical Therapy
| Complication | Mechanism |
|---|---|
| Chemical cystitis | Direct cytotoxic effect of the alkylating agent on the normal bladder urothelium → inflammation → frequency, urgency, dysuria [1][2] |
| Skin rash (contact dermatitis) | Drug leaks onto perineal skin (via catheter drainage or vulvar contact) → allergic/irritant dermatitis [1][2] |
| Myelosuppression (rare) | Systemic absorption through denuded urothelium — unusual because MMC is a large molecule with limited absorption |
| Bladder contracture (rare, with repeated doses) | Chronic inflammation → fibrosis → reduced bladder capacity |
BCG complications are divided into local and systemic, reflecting whether the live attenuated M. bovis organisms remain confined to the bladder or disseminate.
| Category | Complication | Mechanism | Management |
|---|---|---|---|
| Local | BCG cystitis (most common) | Local immune/inflammatory response to BCG organisms on urothelium → frequency, urgency, dysuria, haematuria [1] | Usually self-limiting (48–72h); analgesics, anticholinergics; withhold next BCG dose if severe |
| Local | Granulomatous prostatitis | BCG organisms spread locally to the prostate via the prostatic ducts → granulomatous inflammation [1] | Anti-TB drugs if symptomatic; usually self-limiting |
| Local | Epididymo-orchitis | BCG descends via the vas deferens → granulomatous inflammation of epididymis/testis [1] | Anti-TB drugs; may require orchiectomy in severe cases |
| Systemic | BCG sepsis | BCG organisms enter the bloodstream through damaged urothelium (especially if instilled too soon after TURBT, traumatic catheterisation, or during active haematuria) → disseminated mycobacterial infection [1] | Medical emergency: anti-TB drugs (isoniazid + rifampicin + ethambutol) + high-dose corticosteroids + ICU support [2] |
| Systemic | Pneumonitis | Haematogenous spread of BCG to lungs → granulomatous pneumonitis [1] | Anti-TB drugs + steroids |
| Systemic | Hepatitis | Haematogenous spread → granulomatous hepatitis [1] | Anti-TB drugs + steroids |
| Systemic | Reactive arthritis | Immune-mediated (not direct infection) — molecular mimicry between mycobacterial antigens and joint antigens → sterile joint inflammation [1] | NSAIDs; steroids if severe |
Preventing BCG Sepsis
BCG instillation is contraindicated if: < 2 weeks post-TURBT (raw surface), gross haematuria (exposed vessels), traumatic catheterisation (urethral injury), symptomatic UTI (impaired local immunity). Breaking these rules risks fatal BCG sepsis [3].
Complication of surgery: Radical cystectomy [4]
Radical cystectomy is a major operation with significant morbidity (~30–60% overall complication rate) and 1–3% perioperative mortality.
| Category | Complication | Mechanism |
|---|---|---|
| General surgical | Bleeding, wound infection, DVT/PE | Major pelvic surgery → extensive raw surface, venous stasis, hypercoagulability |
| Anastomotic | Anastomotic leakage and stricture (bowel anastomosis; ureteric-enteral anastomosis) [2] | Ischaemia at suture line → dehiscence (leakage) or excessive fibrosis (stricture); ureteroileal stricture → hydronephrosis |
| Lymphatic | Lymphocele [2] | Pelvic LN dissection disrupts lymphatic channels → lymph fluid accumulates in the pelvis → cystic collection; may cause DVT (compress iliac veins) or become infected |
| GI | Post-operative ileus [2] | Bowel handling during surgery → temporary paralysis of peristalsis (reflex ileus); aggravated by opioid analgesia |
| GI | Bowel injury [2] | Inadvertent enterotomy during dissection around the bladder/bowel adhesions |
| GI | Small bowel obstruction | Adhesions from surgery → mechanical obstruction (may present weeks to years later) |
| Urological | Erectile dysfunction [2] | Damage to the cavernous nerves (branches of the pelvic plexus S2–S4) running along the posterolateral surface of the prostate → loss of parasympathetic-mediated penile erection. Consider nerve-sparing surgery if young + early stage low-grade disease [2] |
| Urological | Urinary stress incontinence [2] | Removal of the prostate (which provides passive continence through the prostatic urethra and internal sphincter) → reliance on external sphincter alone → stress incontinence |
| Urological | Residual tumour / recurrence [2] | Positive surgical margins; micrometastatic disease; field cancerisation → new primary tumours in remaining urothelium (urethra, upper tract) |
| Complication | Type of Diversion | Mechanism |
|---|---|---|
| Hyperchloraemic metabolic acidosis | Ileal conduit, neobladder (any bowel segment in contact with urine) | Bowel mucosa actively reabsorbs Cl⁻ and NH₄⁺ from urine and secretes HCO₃⁻ → net gain of acid equivalents → normal anion gap metabolic acidosis. Longer contact time (neobladder > conduit) = greater risk |
| Vitamin B12 deficiency | If terminal ileum is used | Terminal ileum is the exclusive site of B12 absorption; resection → malabsorption → megaloblastic anaemia, peripheral neuropathy (onset typically > 3–5 years post-surgery) |
| Urinary stasis → recurrent UTI | Neobladder, continent pouch | Bowel segments cannot contract voluntarily like detrusor → incomplete emptying → urinary stasis → bacterial colonisation [2] |
| Urinary stone formation | All types | Mucus production by bowel epithelium → nidus for stone formation; chronic UTI with urease-producing organisms (Proteus) → struvite stones; metabolic acidosis → uric acid stones |
| Stomal complications | Ileal conduit, continent pouch | Stenosis (fibrosis of stoma site → obstruction), parastomal hernia (fascial defect around stoma), skin irritation (contact dermatitis from urine) |
| Ureteroileal stricture | Ileal conduit, neobladder | Fibrosis at the uretero-enteral anastomosis → obstruction → hydronephrosis → silent renal impairment |
| Neobladder-specific: nocturnal incontinence | Orthotopic neobladder | External sphincter relaxes during sleep → urine leaks (neobladder lacks the tonic contraction of detrusor/bladder neck); patients must set alarms for overnight emptying |
| Neobladder-specific: hypercontinence / retention | Orthotopic neobladder | Bowel segment mucus + inability to generate coordinated detrusor contraction → patient must Valsalva / strain to void; some need intermittent self-catheterisation |
| Malignancy at ureterosigmoidostomy site | Ureterosigmoidostomy (rare, historical) | Mixing of urine and faecal stream → bacterial conversion of urinary nitrates to nitrosamines (carcinogens) → adenocarcinoma at the anastomotic site (latency ~20–30 years) |
| Complication | Mechanism |
|---|---|
| Nephrotoxicity | Cisplatin directly damages proximal tubular cells → acute tubular necrosis; requires aggressive hydration and monitoring of GFR; cisplatin-ineligible if GFR < 60 mL/min |
| Ototoxicity | Cisplatin damages cochlear hair cells (irreversible) → high-frequency sensorineural hearing loss, tinnitus |
| Peripheral neuropathy | Cisplatin accumulates in dorsal root ganglia → axonal degeneration → "stocking-glove" sensory neuropathy |
| Myelosuppression | All cytotoxic agents suppress bone marrow → neutropenia (infection risk), thrombocytopenia (bleeding risk), anaemia |
| Nausea and vomiting | Cisplatin is one of the most emetogenic chemotherapy agents → stimulates the chemoreceptor trigger zone (area postrema) and peripheral 5-HT3 receptors on vagal afferents |
| Tumour lysis syndrome (rare) | Rapid tumour cell death → release of intracellular contents (K⁺, PO₄³⁻, uric acid) → hyperkalaemia, hyperphosphataemia, hyperuricaemia, hypocalcaemia, AKI |
| Complication | Timing | Mechanism |
|---|---|---|
| Radiation cystitis | Acute (during/shortly after RT) or late (months–years) | Radiation damages urothelial and submucosal cells → acute inflammation → chronic: endarteritis obliterans → mucosal ischaemia → telangiectasia → haemorrhagic cystitis |
| Radiation proctitis | Acute or late | Same mechanism affecting the rectum → diarrhoea, rectal bleeding, tenesmus |
| Radiation enteritis | Late | Small bowel within the radiation field → fibrosis → strictures → obstruction, malabsorption |
| Secondary malignancy | Very late (years–decades) | Radiation-induced DNA damage in surrounding pelvic tissues → new primary cancers (rectal, uterine, sarcoma) |
| Sexual dysfunction | Late | Damage to neurovascular bundles and pudendal vasculature → erectile dysfunction (males), vaginal stenosis/dryness (females) |
| Pelvic insufficiency fractures | Late | Radiation-induced bone demineralisation → fragility fractures of sacrum, pubis |
| Complication | Mechanism |
|---|---|
| Immune-related adverse events (irAEs) | Blocking PD-1/PD-L1 "releases the brakes" on T cells → T cells attack not only tumour but also normal tissues (autoimmune-like) |
| Specific irAEs: colitis, hepatitis, pneumonitis, thyroiditis/hypothyroidism, hypophysitis, dermatitis, nephritis, myocarditis | Each represents T-cell-mediated inflammation of the respective organ |
| Management | Mild: withhold drug, supportive care; Moderate–severe: systemic corticosteroids; Refractory: additional immunosuppression (infliximab, mycophenolate) |
| Complication | Explanation |
|---|---|
| Psychological burden | Lifelong cystoscopy → chronic anxiety ("cancer surveillance fatigue"); significant impact on quality of life |
| Cystoscopy-related complications | UTI (urethral instrumentation), haematuria (biopsy site), urethral trauma/stricture (repeated instrumentation), pain/discomfort |
| Radiation exposure | Repeated CT urograms for upper tract surveillance → cumulative radiation dose |
| Financial burden | NMIBC is one of the most expensive cancers to manage per patient (from diagnosis to death) due to the sheer volume and duration of surveillance |
| Complication | Significance |
|---|---|
| NMIBC recurrence | 70% lifetime risk of tumour recurrence [3] — this is the defining feature of bladder cancer and the reason for lifelong surveillance |
| NMIBC progression to MIBC | 10–20% of NMIBC will progress to MIBC [3]; high-grade T1 and CIS have the highest progression risk (30–40%) [1] |
| Metachronous upper tract tumours | Field cancerisation → secondary primary tumours can develop in urothelium anywhere along the urinary tract including the renal pelvis, ureter, urethra and bladder [1] |
| MIBC untreated | > 90% 2-year mortality if untreated [3] |
High Yield Summary
Disease complications:
- Hydronephrosis/hydroureter from ureteric obstruction (most common local complication of invasive bladder tumours) → can cause post-renal AKI
- Fistulae: vesicocolic (pneumaturia), vesicovaginal (continuous urinary incontinence) — indicate T4a disease
- Metastases: liver, lung, bone → organ-specific complications (jaundice, dyspnoea, pathological fractures, spinal cord compression)
- VTE: Trousseau syndrome
- 70% lifetime recurrence risk for NMIBC; 10–20% progress to MIBC
TURBT complications: Bleeding, infection, TUR syndrome (dilutional hyponatraemia from hypotonic irrigation fluid), obturator kick (lateral wall diathermy → obturator nerve stimulation → adductor spasm → bladder perforation risk), bladder perforation
Intravesical therapy complications:
- Mitomycin C: chemical cystitis, rash
- BCG: local (cystitis, prostatitis, epididymitis) and systemic (BCG sepsis — treat with anti-TB drugs + steroids; prevent by respecting contraindications)
Radical cystectomy complications: Anastomotic leak/stricture, lymphocele, erectile dysfunction (cavernous nerve damage), urinary stress incontinence (prostate removal), bowel injury, ileus, residual tumour
Urinary diversion complications: Hyperchloraemic metabolic acidosis (bowel reabsorbs Cl⁻/NH₄⁺), vitamin B12 deficiency (terminal ileum resection), urinary stasis → UTI/stones, stomal complications, ureteroileal stricture
Chemotherapy complications: Cisplatin — nephrotoxicity, ototoxicity, peripheral neuropathy, severe emetogenicity, myelosuppression
Immunotherapy complications: Immune-related adverse events (irAEs) — colitis, hepatitis, pneumonitis, thyroiditis, dermatitis → manage with steroids
Active Recall - Bladder Cancer Complications
[1] Senior notes: felixlai.md (Urothelial bladder cancer — Complications, Treatment sections) [2] Senior notes: maxim.md (Bladder cancer — Complications of cystectomy, Urinary diversion, Intravesical therapy) [3] Senior notes: Ryan Ho Urogenital.pdf (Section 7.4.1 Bladder Cancer — Clinical presentation complications, TURBT risks, Intravesical therapy, Radical cystectomy, Prognosis, pp. 153–158) [4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (p. 45 — Complication of surgery) [5] Senior notes: Ryan Ho Fundamentals.pdf (Haematuria complications, p. 342) [6] Senior notes: Ryan Ho Critical Care.pdf (AKI — post-renal causes, p. 25)
High Yield Summary
Definition: Malignant neoplasm of the bladder, ~90% urothelial carcinoma. Key question: muscle-invasive or not?
Epidemiology: 9th commonest cancer worldwide; M:F = 3:1; median age ~70; 9th commonest male cancer in HK.
Risk Factors (UCC): Smoking (#1, 2–5× risk, ~50% attributable), occupational chemical exposure (aromatic amines; latency > 20 years), cyclophosphamide, aristolochic acid (TCM — HK!), pelvic radiation, upper tract UC (field cancerization).
Risk Factors (SCC): Schistosomiasis, bladder stones, long-term indwelling catheter (16–20× risk for SCC).
Risk Factors (Adeno): Urachal remnants, bladder exstrophy.
Pathology: Urothelial (90%), SCC (5–9%), Adenocarcinoma (~1%), Small cell (rare but very aggressive), Sarcomatoid (rare, poor prognosis).
Two-pathway model: Low-grade papillary (FGFR3 mutations, high recurrence, low progression) vs High-grade/CIS (TP53/RB1 loss, high progression to MIBC).
Staging: NMIBC (Tis, Ta, T1) vs MIBC (≥T2). Muscle-invasive tumours are mostly high-grade.
Cardinal symptom: Painless gross haematuria throughout the stream. Any unexplained haematuria > 40 years = cancer until proven otherwise.
CIS pitfall: Presents with irritative LUTS, NOT visible haematuria — mimics UTI/OAB.
Advanced disease signs: Pain (flank, suprapubic, bony), constitutional symptoms, pneumaturia (vesicocolic fistula), fixed pelvic mass on EUA (T4b).
Metastases: Liver, lung, bone.
Field cancerization: Multifocal occurrence; upper tract → 17% concurrent bladder CA; bladder → only 2% upper tract CA (antegrade flow).
High Yield Summary
The DDx of bladder cancer is essentially the DDx of haematuria, organized anatomically from kidney to urethra plus systemic causes.
Most common cause of haematuria overall: UTI (13%). Most worrying: malignancy (CA bladder 12%, RCC 0.6%) [2][3].
Most common cause of gross haematuria in patients > 50: bladder cancer [5].
Key discriminators:
- Glomerular vs urological: dysmorphic RBCs/casts/proteinuria = glomerular; isomorphic RBCs ± clots = urological
- Painless = malignancy until proven otherwise; painful = stone, UTI, infarction
- Throughout stream = bladder/upper tract; initial = urethra; terminal = bladder neck/prostate
- Blood clots = urological (urokinase in glomerular filtrate prevents clots in GN)
- Irritative LUTS refractory to antibiotics in elderly = CIS until proven otherwise
DDx of bladder mass: Primary malignant (urothelial 90%, SCC, adeno, small cell, sarcomatoid), secondary malignant (colon, rectum, prostate, cervix), benign (papilloma, nephrogenic adenoma, cystitis cystica, endometriosis, blood clot)
BPH does NOT exclude malignancy — always investigate haematuria fully even if BPH is present.
High Yield Summary
Diagnosis of bladder cancer is histopathological — no single test confirms it; tissue from cystoscopy/TURBT is required.
Diagnostic algorithm: Haematuria workup → urinalysis + cytology → upper tract imaging (CTU preferred) → flexible cystoscopy → TURBT (diagnosis + staging + therapy).
Urine cytology: Low sensitivity (34%) but very high specificity ( > 98%) → any positive = assume malignancy. Best for high-grade/CIS. Send fresh, 2nd morning void x3 days.
Cystoscopy is the gold standard for lower tract; fluorescence/PDD improves CIS detection. Document site, size, number, appearance.
TURBT = pivotal procedure: diagnostic (histology), staging (depth — must include detrusor muscle), and therapeutic (curative for NMIBC).
2nd look TURBT (4–6 weeks): indicated for (1) high-grade/CIS, (2) no detrusor muscle in initial specimen, (3) incomplete initial resection — residual disease in 20–30%.
CTU: preferred upper tract imaging; delayed phase (3–5 min) for filling defects; misses tumours < 1 cm; ~80% accurate for extravesical extension; 68% FP for nodal involvement.
IVU: largely replaced; "Goblet sign" = classic upper tract TCC finding.
Staging Ix for MIBC: CXR/CT thorax, CT A+P, bone scan (if symptomatic); PET-CT with 11C-acetate (FDG not sensitive for bladder CA).
Staging: Ta/Tis/T1 = NMIBC; ≥T2 = MIBC. Grading: PUNLMP → low-grade → high-grade. Low-grade recurs but rarely progresses; high-grade/CIS progresses and metastasises.
High Yield Summary
NMIBC Management (Tis/Ta/T1):
- TURBT is the cornerstone — diagnostic, staging, AND therapeutic
- Immediate post-op intravesical mitomycin C for ALL NMIBC (reduces recurrence by ~30%, NOT progression; immediate because it prevents tumour cell implantation)
- Risk stratify: Low → MMC only; Intermediate → BCG or chemo × 1 year; High → BCG × 1–3 years ± 2nd look TURBT ± radical cystectomy
- BCG is first-line for CIS and reduces BOTH recurrence AND progression (unlike MMC which only reduces recurrence)
- BCG is a live attenuated vaccine (M. bovis) → NEVER give immediately post-TURBT (risk of BCG sepsis)
- BCG regimen: induction weekly × 6 → maintenance weekly × 3 at regular intervals
- BCG side effects: irritative LUTS (local), BCG sepsis (systemic) → treat with anti-TB drugs
- 2nd look TURBT at 4–6 weeks if: (1) high-grade/CIS, (2) no detrusor in specimen, (3) incomplete resection
- Surveillance is LIFELONG: field cancerisation → 70% lifetime recurrence risk
MIBC Management (T2–T4a):
- Neoadjuvant cisplatin-based chemo + Radical cystectomy (open/lap/robotic) + pelvic LND + urinary diversion (most commonly ileal conduit in HK)
- RC removes: M — bladder + prostate + seminal vesicles ± urethra; F — bladder + uterus + HBSO + part of vagina ± urethra
- Pelvic LND provides survival benefit (microscopic mets common)
- Bladder-preserving TMT (maximal TURBT + chemoRT) for unfit/patient preference
Metastatic (T4b/M1):
- 1st line: cisplatin-based chemo (GC or MVAC); carboplatin if cisplatin-ineligible
- 2nd line: immune checkpoint inhibitors (pembrolizumab, atezolizumab)
- Targeted: FGFR inhibitors (erdafitinib) for FGFR-altered tumours
- Maintenance avelumab after 1st-line chemo
- Antibody-drug conjugates (enfortumab vedotin) for refractory disease
T4b = unresectable (pelvic wall/abdominal wall invasion)
High Yield Summary
Disease complications:
- Hydronephrosis/hydroureter from ureteric obstruction (most common local complication of invasive bladder tumours) → can cause post-renal AKI
- Fistulae: vesicocolic (pneumaturia), vesicovaginal (continuous urinary incontinence) — indicate T4a disease
- Metastases: liver, lung, bone → organ-specific complications (jaundice, dyspnoea, pathological fractures, spinal cord compression)
- VTE: Trousseau syndrome
- 70% lifetime recurrence risk for NMIBC; 10–20% progress to MIBC
TURBT complications: Bleeding, infection, TUR syndrome (dilutional hyponatraemia from hypotonic irrigation fluid), obturator kick (lateral wall diathermy → obturator nerve stimulation → adductor spasm → bladder perforation risk), bladder perforation
Intravesical therapy complications:
- Mitomycin C: chemical cystitis, rash
- BCG: local (cystitis, prostatitis, epididymitis) and systemic (BCG sepsis — treat with anti-TB drugs + steroids; prevent by respecting contraindications)
Radical cystectomy complications: Anastomotic leak/stricture, lymphocele, erectile dysfunction (cavernous nerve damage), urinary stress incontinence (prostate removal), bowel injury, ileus, residual tumour
Urinary diversion complications: Hyperchloraemic metabolic acidosis (bowel reabsorbs Cl⁻/NH₄⁺), vitamin B12 deficiency (terminal ileum resection), urinary stasis → UTI/stones, stomal complications, ureteroileal stricture
Chemotherapy complications: Cisplatin — nephrotoxicity, ototoxicity, peripheral neuropathy, severe emetogenicity, myelosuppression
Immunotherapy complications: Immune-related adverse events (irAEs) — colitis, hepatitis, pneumonitis, thyroiditis, dermatitis → manage with steroids
Acute Retention Of Urine
Acute retention of urine is the sudden inability to pass urine voluntarily, resulting in painful distension of the bladder that requires urgent catheterization.
Benign Prostatic Hyperplasia
Benign prostatic hyperplasia is a non-malignant enlargement of the prostate gland due to stromal and epithelial cell proliferation, commonly causing lower urinary tract symptoms in aging men.